The columns are defined after the table.
Sale NDC11 | Sale Proprietary Name | Sale Labeler | Start Date | End Date | Sale GTIN | Sale Last Update | Use NDC11 | No Use NDC | Use GTIN | Use Last Update | CVX Code | CVX Description | MVX Code |
|---|
| 00005-0100-02 | Trumenba | Wyeth Pharmaceutical Division of Wyeth Holdings LLC | 11/5/2014 | 1/28/2026 | 00300050100027 | 2/4/2026 | 00005-0100-01 | False | 00300050100010 | 2/1/2023 | 162 | meningococcal B, recombinant | PFR |
| 00005-0100-05 | Trumenba | Wyeth Pharmaceutical Division of Wyeth Holdings LLC | 11/5/2014 | | 00300050100058 | 11/22/2019 | 00005-0100-01 | False | 00300050100010 | 2/1/2023 | 162 | meningococcal B, recombinant | PFR |
| 00005-0100-10 | Trumenba | Wyeth Pharmaceutical Division of Wyeth Holdings LLC | 11/5/2014 | | 00300050100102 | 11/22/2019 | 00005-0100-01 | False | 00300050100010 | 2/1/2023 | 162 | meningococcal B, recombinant | PFR |
| 00005-1970-50 | Prevnar | Wyeth Pharmaceutical Division of Wyeth Holdings Corporation, a subsidiary of Pfizer Inc. | 3/1/2000 | 12/31/2011 | | 5/30/2018 | 00005-1970-49 | False | | 5/30/2018 | 100 | pneumococcal conjugate PCV 7 | WAL |
| 00005-1971-02 | PREVNAR 13 | Wyeth Pharmaceutical Division of Wyeth Holdings LLC | 3/12/2010 | 9/30/2025 | 00300051971022 | 11/19/2025 | 00005-1971-01 | False | 00300051971015 | 11/19/2025 | 133 | Pneumococcal conjugate PCV 13 | PFR |
| 00005-1971-04 | PREVNAR 13 | Wyeth Pharmaceutical Division of Wyeth Holdings LLC, a subsidiary of Pfizer Inc. | 3/12/2010 | 7/29/2016 | | 2/3/2023 | 00005-1971-01 | False | 00300051971015 | 11/19/2025 | 133 | Pneumococcal conjugate PCV 13 | PFR |
| 00005-1971-05 | PREVNAR 13 | Wyeth Pharmaceutical Division of Wyeth Holdings LLC | 3/12/2010 | 9/30/2025 | 00300051971053 | 11/19/2025 | 00005-1971-01 | False | 00300051971015 | 11/19/2025 | 133 | Pneumococcal conjugate PCV 13 | PFR |
| 00005-2000-02 | Prevnar 20 | Wyeth Pharmaceutical Division of Wyeth Holdings LLC | 8/10/2021 | | 00300052000028 | 2/13/2024 | 00005-2000-01 | False | 10300052000018 | 2/13/2024 | 216 | Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF | PFR |
| 00005-2000-10 | Prevnar 20 | Wyeth Pharmaceutical Division of Wyeth Holdings LLC | 8/10/2021 | | 00300052000103 | 2/13/2024 | 00005-2000-01 | False | 10300052000018 | 2/13/2024 | 216 | Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF | PFR |
| 00006-4045-00 | GARDASIL | Merck Sharp & Dohme LLC | 6/8/2006 | | | 7/5/2022 | 00006-4045-01 | False | 00300064045017 | 2/1/2023 | 62 | HPV, quadrivalent | MSD |
| 00006-4045-41 | GARDASIL | Merck Sharp & Dohme LLC | 6/8/2006 | | | 7/5/2022 | 00006-4045-01 | False | 00300064045017 | 2/1/2023 | 62 | HPV, quadrivalent | MSD |
| 00006-4047-20 | RotaTeq | Merck Sharp & Dohme LLC | 2/3/2006 | | 00300064047202 | 5/17/2022 | 00006-4047-02 | False | | 2/1/2023 | 116 | rotavirus, pentavalent | MSD |
| 00006-4047-20 | RotaTeq | Merck Sharp & Dohme LLC | 2/3/2006 | | 00300064047202 | 5/17/2022 | 00006-4047-01 | False | 00300064047011 | 2/1/2023 | 116 | rotavirus, pentavalent | MSD |
| 00006-4047-41 | RotaTeq | Merck Sharp & Dohme LLC | 2/3/2006 | | 00300064047417 | 5/17/2022 | 00006-4047-02 | False | | 2/1/2023 | 116 | rotavirus, pentavalent | MSD |
| 00006-4047-41 | RotaTeq | Merck Sharp & Dohme LLC | 2/3/2006 | | 00300064047417 | 5/17/2022 | 00006-4047-01 | False | 00300064047011 | 2/1/2023 | 116 | rotavirus, pentavalent | MSD |
| 00006-4093-02 | RECOMBIVAX HB | Merck Sharp & Dohme LLC | 7/23/1986 | | 00300064093025 | 7/5/2022 | 00006-4093-01 | False | 00300064093018 | 2/1/2023 | 08 | Hep B, adolescent or pediatric | MSD |
| 00006-4093-09 | RECOMBIVAX HB | Merck Sharp & Dohme LLC | 7/23/1986 | 6/13/2023 | 00300064093094 | 7/11/2023 | 00006-4093-01 | False | 00300064093018 | 2/1/2023 | 08 | Hep B, adolescent or pediatric | MSD |
| 00006-4094-02 | RECOMBIVAX HB | Merck Sharp & Dohme LLC | 7/23/1986 | | 00300064094022 | 7/5/2022 | 00006-4094-01 | False | 00300064094015 | 2/1/2023 | 43 | Hep B, adult | MSD |
| 00006-4094-09 | RECOMBIVAX HB | Merck Sharp & Dohme LLC | 7/23/1986 | 6/13/2023 | 00300064094091 | 7/11/2023 | 00006-4094-01 | False | 00300064094015 | 2/1/2023 | 43 | Hep B, adult | MSD |
| 00006-4095-02 | VAQTA | Merck Sharp & Dohme LLC | 3/29/1996 | | 00300064095029 | 7/5/2022 | 00006-4095-01 | False | 00300064095012 | 2/1/2023 | 83 | Hep A, ped/adol, 2 dose | MSD |
| 00006-4095-09 | VAQTA | Merck Sharp & Dohme Corp. | 3/29/1996 | 4/30/2019 | 00300064095098 | 5/21/2019 | 00006-4095-01 | False | 00300064095012 | 2/1/2023 | 83 | Hep A, ped/adol, 2 dose | MSD |
| 00006-4096-02 | VAQTA | Merck Sharp & Dohme LLC | 3/29/1996 | | 00300064096026 | 7/5/2022 | 00006-4096-01 | False | 00300064096019 | 2/1/2023 | 52 | Hep A, adult | MSD |
| 00006-4096-09 | VAQTA | Merck Sharp & Dohme Corp. | 3/29/1996 | 4/30/2019 | 00300064096095 | 5/21/2019 | 00006-4096-01 | False | 00300064096019 | 2/1/2023 | 52 | Hep A, adult | MSD |
| 00006-4109-02 | GARDASIL | Merck Sharp & Dohme LLC | 6/8/2006 | | | 7/5/2022 | 00006-4109-01 | False | 00300064109016 | 2/1/2023 | 62 | HPV, quadrivalent | MSD |
| 00006-4109-09 | GARDASIL | Merck Sharp & Dohme LLC | 6/8/2006 | | | 7/5/2022 | 00006-4109-01 | False | 00300064109016 | 2/1/2023 | 62 | HPV, quadrivalent | MSD |
| 00006-4119-02 | GARDASIL 9 | Merck Sharp & Dohme Corp. | 12/10/2014 | 4/30/2019 | 00300064119022 | 5/29/2019 | 00006-4119-01 | False | 00300064119015 | 2/1/2023 | 165 | HPV9 | MSD |
| 00006-4119-03 | GARDASIL 9 | Merck Sharp & Dohme LLC | 12/10/2014 | | 00300064119039 | 6/22/2022 | 00006-4119-01 | False | 00300064119015 | 2/1/2023 | 165 | HPV9 | MSD |
| 00006-4121-02 | GARDASIL 9 | Merck Sharp & Dohme LLC | 12/10/2014 | | 00300064121025 | 6/22/2022 | 00006-4121-01 | False | 00300064121018 | 2/1/2023 | 165 | HPV9 | MSD |
| 00006-4133-41 | Tetanus and Diphtheria Toxoids Adsorbed | Merck Sharp & Dohme Corp. | 7/27/1970 | 6/2/2014 | | 7/22/2014 | 00006-4133-01 | False | | 7/3/2018 | 09 | Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed | MSD |
| 00006-4171-00 | ProQuad | Merck Sharp & Dohme LLC | 8/1/2015 | | 00300064171006 | 1/6/2026 | 00006-4171-01 | False | 00300064171013 | 1/6/2026 | 94 | MMRV | MSD |
| 00006-4293-02 | ERVEBO | Merck Sharp & Dohme LLC | 12/19/2019 | | | 1/6/2023 | 00006-4293-01 | False | | 2/1/2023 | 204 | Ebola Zaire vaccine, live, recombinant, 1mL dose | MSD |
| 00006-4329-02 | VAXNEUVANCE | Merck Sharp & Dohme LLC | 7/16/2021 | | 00300064329025 | 10/17/2022 | 00006-4329-01 | False | 00300064329018 | 2/1/2023 | 215 | Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF | MSD |
| 00006-4329-03 | VAXNEUVANCE | Merck Sharp & Dohme LLC | 7/16/2021 | | 00300064329032 | 10/17/2022 | 00006-4329-01 | False | 00300064329018 | 2/1/2023 | 215 | Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF | MSD |
| 00006-4347-01 | CAPVAXIVE | Merck Sharp & Dohme LLC | 6/17/2024 | | | 7/12/2024 | 00006-4347-99 | False | | 7/11/2024 | 327 | Pneumococcal conjugate PCV21, polysaccharide CRM197 conjugate, PF | MSD |
| 00006-4347-02 | CAPVAXIVE | Merck Sharp & Dohme LLC | 6/17/2024 | | | 7/12/2024 | 00006-4347-99 | False | | 7/11/2024 | 327 | Pneumococcal conjugate PCV21, polysaccharide CRM197 conjugate, PF | MSD |
| 00006-4379-02 | RotaTeq | Merck Sharp & Dohme LLC | 5/15/2026 | | | 6/10/2026 | 00006-4379-01 | False | | 6/10/2026 | 116 | rotavirus, pentavalent | MSD |
| 00006-4681-00 | M-M-R II | Merck Sharp & Dohme LLC | 4/21/1971 | | 00300064681000 | 1/6/2026 | 00006-4681-01 | False | 00300064681017 | 1/6/2026 | 03 | MMR | MSD |
| 00006-4739-00 | PNEUMOVAX 23 | Merck Sharp & Dohme Corp. | 7/7/1983 | 4/30/2019 | | 5/21/2019 | 00006-4739-01 | False | 00300064739015 | 5/21/2019 | 33 | pneumococcal polysaccharide PPV23 | MSD |
| 00006-4826-00 | VARIVAX | Merck Sharp & Dohme LLC | 3/17/1995 | 6/13/2023 | 00300064826005 | 7/11/2023 | 00006-4826-01 | False | 00300064826012 | 10/26/2023 | 21 | varicella | MSD |
| 00006-4827-00 | VARIVAX | Merck Sharp & Dohme LLC | 3/17/1995 | | 00300064827002 | 7/5/2022 | 00006-4827-01 | False | 00300064827019 | 2/1/2023 | 21 | varicella | MSD |
| 00006-4831-41 | VAQTA | Merck Sharp & Dohme LLC | 3/29/1996 | | 00300064831412 | 7/5/2022 | 00006-4831-01 | False | 00300064831016 | 2/1/2023 | 83 | Hep A, ped/adol, 2 dose | MSD |
| 00006-4837-02 | PNEUMOVAX 23 | Merck Sharp & Dohme Corp. | 7/21/2014 | 1/1/2020 | | 1/21/2020 | 00006-4837-01 | False | 00300064837018 | 2/1/2023 | 33 | pneumococcal polysaccharide PPV23 | MSD |
| 00006-4837-03 | PNEUMOVAX 23 | Merck Sharp & Dohme LLC | 5/30/2014 | | 00300064837032 | 5/30/2023 | 00006-4837-01 | False | 00300064837018 | 2/1/2023 | 33 | pneumococcal polysaccharide PPV23 | MSD |
| 00006-4841-00 | VAQTA | Merck Sharp & Dohme LLC | 3/29/1996 | | 00300064841008 | 7/5/2022 | 00006-4841-01 | False | 00300064841015 | 2/1/2023 | 52 | Hep A, adult | MSD |
| 00006-4841-41 | VAQTA | Merck Sharp & Dohme LLC | 3/29/1996 | | 00300064841411 | 7/5/2022 | 00006-4841-01 | False | 00300064841015 | 2/1/2023 | 52 | Hep A, adult | MSD |
| 00006-4897-00 | PedvaxHIB | Merck Sharp & Dohme LLC | 12/20/1989 | | 00300064897005 | 6/22/2022 | 00006-4897-01 | False | 00300064897012 | 2/1/2023 | 49 | Hib (PRP-OMP) | MSD |
| 00006-4898-00 | COMVAX | Merck Sharp & Dohme Corp. | 10/2/1996 | 12/31/2014 | | 5/30/2018 | 00006-4898-01 | False | 00300064898019 | 5/30/2018 | 51 | Hib-Hep B | MSD |
| 00006-4943-00 | PNEUMOVAX 23 | Merck Sharp & Dohme LLC | 7/7/1983 | | 00300064943009 | 6/13/2022 | 00006-4943-01 | False | 00300064943016 | 2/1/2023 | 33 | pneumococcal polysaccharide PPV23 | MSD |
| 00006-4963-00 | ZOSTAVAX | Merck Sharp & Dohme LLC | 5/25/2006 | 9/19/2022 | 00300064963007 | 10/17/2022 | 00006-4963-01 | False | 00300064963014 | 10/17/2022 | 121 | zoster live | MSD |
| 00006-4963-41 | ZOSTAVAX | Merck Sharp & Dohme LLC | 5/25/2006 | 9/19/2022 | 00300064963410 | 10/17/2022 | 00006-4963-01 | False | 00300064963014 | 10/17/2022 | 121 | zoster live | MSD |
| 00006-4980-00 | RECOMBIVAX HB | Merck Sharp & Dohme Corp. | 7/23/1986 | 9/19/2008 | | 7/13/2018 | 00006-4980-00 | True | | 11/20/2017 | 08 | Hep B, adolescent or pediatric | MSD |
| 00006-4981-00 | RECOMBIVAX HB | Merck Sharp & Dohme LLC | 7/23/1986 | | 00300064981001 | 7/5/2022 | 00006-4981-01 | False | 00300064981018 | 2/1/2023 | 08 | Hep B, adolescent or pediatric | MSD |
| 00006-4992-00 | RECOMBIVAX HB | Merck Sharp & Dohme LLC | 7/23/1986 | | 00300064992007 | 7/5/2022 | 00006-4992-01 | False | 00300064992014 | 2/1/2023 | 44 | Hep B, high-dosage, dialysis or IC | MSD |
| 00006-4995-00 | RECOMBIVAX HB | Merck Sharp & Dohme LLC | 7/23/1986 | | 00300064995008 | 7/5/2022 | 00006-4995-01 | False | 00300064995015 | 2/1/2023 | 43 | Hep B, adult | MSD |
| 00006-4995-41 | RECOMBIVAX HB | Merck Sharp & Dohme LLC | 7/23/1986 | | 00300064995411 | 7/5/2022 | 00006-4995-01 | False | 00300064995015 | 2/1/2023 | 43 | Hep B, adult | MSD |
| 00006-4999-00 | ProQuad | Merck Sharp & Dohme Corp. | 9/6/2005 | 7/31/2015 | 00300064999006 | 9/13/2018 | 00006-4999-01 | False | 00300064999013 | 9/13/2018 | 94 | MMRV | MSD |
| 00006-5073-01 | ENFLONSIA | Merck Sharp & Dohme LLC | 6/9/2025 | | | 7/2/2025 | 00006-5073-99 | False | | 7/2/2025 | 332 | RSV, mAb, clesrovimab-cfor, 0.7 mL, neonate and infant, PF | MSD |
| 00006-5073-02 | ENFLONSIA | Merck Sharp & Dohme LLC | 6/9/2025 | | | 7/2/2025 | 00006-5073-99 | False | | 7/2/2025 | 332 | RSV, mAb, clesrovimab-cfor, 0.7 mL, neonate and infant, PF | MSD |
| 00052-0603-02 | BCG VACCINE | Merck Sharp & Dohme LLC | 6/21/1989 | | | 6/22/2022 | 00052-0603-01 | False | | 2/1/2023 | 19 | BCG | MSD |
| 00069-0297-02 | TicoVac | Pfizer Laboratories Div Pfizer Inc | 6/27/2022 | | 00300690297026 | 10/17/2022 | 00069-0297-01 | False | 10300690297016 | 2/1/2023 | 223 | Tick-borne encephalitis, inactivated, PF, 0.25mL | PFR |
| 00069-0297-10 | TicoVac | Pfizer Laboratories Div Pfizer Inc | 6/27/2022 | | 00300690297101 | 10/17/2022 | 00069-0297-01 | False | 10300690297016 | 2/1/2023 | 223 | Tick-borne encephalitis, inactivated, PF, 0.25mL | PFR |
| 00069-0344-01 | Abrysvo | Pfizer Laboratories Div Pfizer Inc | 7/12/2023 | 5/31/2026 | 00300690344010 | 6/16/2026 | 00069-0207-01 | False | 10300690207015 | 6/9/2026 | 305 | RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF | PFR |
| 00069-0344-05 | Abrysvo | Pfizer Laboratories Div Pfizer Inc | 7/12/2023 | 5/31/2026 | 00300690344058 | 6/10/2026 | 00069-0207-01 | False | 10300690207015 | 6/9/2026 | 305 | RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF | PFR |
| 00069-0344-10 | Abrysvo | Pfizer Laboratories Div Pfizer Inc | 7/12/2023 | 5/31/2026 | 00300690344102 | 6/10/2026 | 00069-0207-01 | False | 10300690207015 | 6/9/2026 | 305 | RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF | PFR |
| 00069-0411-02 | TicoVac | Pfizer Laboratories Div Pfizer Inc | 10/25/2021 | | 00300690411026 | 10/18/2022 | 00069-0411-01 | False | 10300690411016 | 2/1/2023 | 224 | Tick-borne encephalitis, inactivated, PF, 0.5mL | PFR |
| 00069-0411-10 | TicoVac | Pfizer Laboratories Div Pfizer Inc | 10/25/2021 | | 00300690411101 | 10/18/2022 | 00069-0411-01 | False | 10300690411016 | 2/1/2023 | 224 | Tick-borne encephalitis, inactivated, PF, 0.5mL | PFR |
| 00069-0600-01 | PENBRAYA | Pfizer Laboratories Div Pfizer Inc | 11/27/2023 | | 00300690600017 | 3/18/2025 | 00069-0332-01 | False | 10300690332014 | 3/18/2025 | 316 | Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF | PFR |
| 00069-0600-01 | PENBRAYA | Pfizer Laboratories Div Pfizer Inc | 11/27/2023 | | 00300690600017 | 3/18/2025 | 00069-0271-01 | False | 10300690271016 | 3/18/2025 | 316 | Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF | PFR |
| 00069-0600-05 | PENBRAYA | Pfizer Laboratories Div Pfizer Inc | 11/27/2023 | | 00300690600055 | 3/18/2025 | 00069-0271-01 | False | 10300690271016 | 3/18/2025 | 316 | Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF | PFR |
| 00069-0600-05 | PENBRAYA | Pfizer Laboratories Div Pfizer Inc | 11/27/2023 | | 00300690600055 | 3/18/2025 | 00069-0332-01 | False | 10300690332014 | 3/18/2025 | 316 | Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF | PFR |
| 00069-0600-10 | PENBRAYA | Pfizer Laboratories Div Pfizer Inc | 11/27/2023 | | 00300690600109 | 3/18/2025 | 00069-0332-01 | False | 10300690332014 | 3/18/2025 | 316 | Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF | PFR |
| 00069-0600-10 | PENBRAYA | Pfizer Laboratories Div Pfizer Inc | 11/27/2023 | | 00300690600109 | 3/18/2025 | 00069-0271-01 | False | 10300690271016 | 3/18/2025 | 316 | Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF | PFR |
| 00069-2025-10 | Comirnaty | Pfizer Laboratories Div Pfizer Inc | 5/18/2022 | 9/11/2023 | 00300692025108 | 2/6/2024 | 00069-2025-01 | False | 10300692025013 | 2/6/2024 | 217 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose | PFR |
| 00069-2025-25 | Comirnaty | Pfizer Laboratories Div Pfizer Inc | 3/1/2022 | 9/11/2023 | 00300692025252 | 2/6/2024 | 00069-2025-01 | False | 10300692025013 | 2/6/2024 | 217 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose | PFR |
| 00069-2362-10 | Comirnaty | Pfizer Laboratories Div Pfizer Inc | 9/11/2023 | 8/21/2024 | 00300692362104 | 2/11/2025 | 00069-2362-01 | False | 10300692362019 | 2/11/2025 | 309 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL | PFR |
| 00069-2377-10 | Comirnaty | Pfizer Laboratories Div Pfizer Inc | 10/31/2023 | 8/21/2024 | 00300692377108 | 9/19/2024 | 00069-2377-01 | False | 10300692377013 | 9/19/2024 | 309 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL | PFR |
| 00069-2392-10 | Comirnaty | Pfizer Laboratories Div Pfizer Inc | 9/11/2023 | 6/30/2024 | | 7/18/2024 | 00069-2392-01 | False | | 7/18/2024 | 309 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL | PFR |
| 00069-2432-10 | Comirnaty | Pfizer Laboratories Div Pfizer Inc | 8/22/2024 | 1/22/2026 | 00300692432104 | 2/4/2026 | 00069-2432-01 | False | 10300692432019 | 2/4/2026 | 309 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL | PFR |
| 00069-2465-01 | Abrysvo | Pfizer Laboratories Div Pfizer Inc | 7/30/2024 | | 00300692465010 | 5/13/2025 | 00069-2465-19 | False | 10300692465192 | 5/13/2025 | 305 | RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF | PFR |
| 00069-2465-10 | Abrysvo | Pfizer Laboratories Div Pfizer Inc | 7/30/2024 | | 00300692465102 | 5/13/2025 | 00069-2465-19 | False | 10300692465192 | 5/13/2025 | 305 | RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF | PFR |
| 00069-2501-10 | Comirnaty | Pfizer Laboratories Div Pfizer Inc | 8/27/2025 | | | 9/9/2025 | 00069-2501-01 | False | | 9/9/2025 | 310 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL | PFR |
| 00069-2528-10 | Comirnaty | Pfizer Laboratories Div Pfizer Inc | 8/27/2025 | | | 9/9/2025 | 00069-2528-01 | False | | 9/9/2025 | 309 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL | PFR |
| 13533-0131-01 | TDVAX | Grifols USA, LLC | 7/1/2015 | 3/31/2025 | 20313533131016 | 4/8/2025 | 13533-0131-00 | False | 00313533131005 | 4/22/2025 | 09 | Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed | MBL |
| 14362-0111-04 | TDVAX | MassBiologics | 7/27/1970 | 3/31/2025 | 20314362011142 | 4/8/2025 | 14362-0111-03 | False | 00314362011131 | 4/22/2025 | 09 | Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed | MBL |
| 17478-0131-01 | Tetanus and Diphtheria Toxoids Adsorbed | Akorn, Inc. | 2/15/2013 | 4/27/2017 | | 7/6/2018 | 17478-0131-00 | False | | 5/30/2018 | 09 | Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed | MBL |
| 19515-0808-52 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/1/2022 | 6/30/2023 | 00319515808521 | 7/18/2024 | 19515-0808-41 | False | 10319515808412 | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | IDB |
| 19515-0810-52 | FLULAVAL | ID Biomedical Corporation of Quebec | 7/1/2024 | 6/30/2025 | | 7/16/2025 | 19515-0810-41 | False | | 7/16/2025 | 140 | Influenza, split virus, trivalent, PF | IDB |
| 19515-0814-52 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/1/2023 | 6/30/2024 | | 7/18/2024 | 19515-0814-41 | False | | 7/23/2024 | 150 | Influenza, split virus, quadrivalent, PF | IDB |
| 19515-0816-52 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/2/2020 | 6/30/2021 | | 7/18/2024 | 19515-0816-41 | False | | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | IDB |
| 19515-0818-52 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/2/2021 | 6/30/2022 | 00319515818520 | 7/18/2024 | 19515-0818-41 | False | 10319515818411 | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | IDB |
| 19515-0845-11 | FLULAVAL | ID Biomedical | 10/30/2015 | 10/31/2015 | | 7/12/2018 | 19515-0845-01 | False | | 7/3/2018 | 141 | Influenza, split virus, trivalent, preservative | IDB |
| 19515-0850-52 | FLULAVAL | ID Biomedical | 7/1/2015 | 10/31/2015 | | 7/12/2018 | 19515-0850-41 | False | | 7/3/2018 | 140 | Influenza, split virus, trivalent, PF | IDB |
| 19515-0889-07 | FLULAVAL | ID Biomedical Corporation of Quebec | 7/20/2012 | 7/1/2013 | | 12/7/2017 | 19515-0889-02 | False | | 11/20/2017 | 141 | Influenza, split virus, trivalent, preservative | IDB |
| 19515-0890-07 | FLULAVAL | ID Biomedical Corporation of Quebec | 7/1/2013 | 6/30/2014 | | 12/7/2017 | 19515-0890-02 | False | | 11/20/2017 | 141 | Influenza, split virus, trivalent, preservative | IDB |
| 19515-0891-11 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/1/2014 | 6/30/2015 | | 5/30/2018 | 19515-0891-01 | False | | 5/30/2018 | 158 | Influenza, split virus, quadrivalent, preservative | IDB |
| 19515-0893-07 | FLULAVAL | ID Biomedical Corporation of Quebec | 7/1/2014 | 6/30/2015 | | 5/30/2018 | 19515-0893-02 | False | 00319515893022 | 5/30/2018 | 141 | Influenza, split virus, trivalent, preservative | IDB |
| 19515-0894-52 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/1/2014 | 6/30/2015 | | 5/30/2018 | 19515-0894-41 | False | | 5/30/2018 | 150 | Influenza, split virus, quadrivalent, PF | IDB |
| 19515-0895-11 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 8/15/2013 | 6/30/2014 | | 12/7/2017 | 19515-0895-01 | False | | 11/20/2017 | 158 | Influenza, split virus, quadrivalent, preservative | IDB |
| 19515-0896-11 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/7/2017 | 6/30/2018 | 00319515896115 | 7/9/2018 | 19515-0896-01 | False | 00319515896016 | 7/9/2018 | 158 | Influenza, split virus, quadrivalent, preservative | IDB |
| 19515-0897-11 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/2/2019 | 6/30/2020 | | 7/18/2024 | 19515-0897-01 | False | | 7/18/2024 | 158 | Influenza, split virus, quadrivalent, preservative | IDB |
| 19515-0898-11 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/1/2015 | 6/30/2016 | | 5/30/2018 | 19515-0898-01 | False | 00319515898010 | 5/30/2018 | 158 | Influenza, split virus, quadrivalent, preservative | IDB |
| 19515-0900-11 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 6/29/2018 | 6/30/2019 | 00319515900119 | 7/16/2019 | 19515-0900-01 | False | 00319515900010 | 7/16/2019 | 158 | Influenza, split virus, quadrivalent, preservative | IDB |
| 19515-0901-52 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/1/2015 | 6/30/2016 | | 5/30/2018 | 19515-0901-41 | False | 00319515901413 | 5/30/2018 | 150 | Influenza, split virus, quadrivalent, PF | IDB |
| 19515-0903-11 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/1/2016 | 6/30/2017 | | 7/11/2018 | 19515-0903-01 | False | | 7/3/2018 | 158 | Influenza, split virus, quadrivalent, preservative | IDB |
| 19515-0904-52 | FLULAVAL | ID Biomedical Corporation of Quebec | 7/1/2025 | | | 7/16/2025 | 19515-0904-41 | False | | 7/16/2025 | 140 | Influenza, split virus, trivalent, PF | IDB |
| 19515-0906-52 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/2/2019 | 6/30/2020 | | 7/18/2024 | 19515-0906-41 | False | | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | IDB |
| 19515-0908-52 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/1/2016 | 6/30/2017 | | 7/11/2018 | 19515-0908-41 | False | | 7/3/2018 | 150 | Influenza, split virus, quadrivalent, PF | IDB |
| 19515-0909-52 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 6/29/2018 | 6/30/2019 | 00319515909525 | 7/16/2019 | 19515-0909-41 | False | 00319515909419 | 7/16/2019 | 150 | Influenza, split virus, quadrivalent, PF | IDB |
| 19515-0912-52 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/7/2017 | 6/30/2018 | 00319515912525 | 7/9/2018 | 19515-0912-41 | False | 00319515912419 | 7/9/2018 | 150 | Influenza, split virus, quadrivalent, PF | IDB |
| 21695-0413-01 | Tetanus and Diphtheria Toxoids Adsorbed | Rebel Distributors | 10/13/1967 | 10/4/2019 | | 10/15/2019 | 21695-0413-01 | True | | 10/11/2019 | 09 | Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed | MBL |
| 33332-0010-01 | AFLURIA | CSL Limited | 7/30/2010 | 6/30/2011 | | 1/29/2018 | 33332-0010-01 | True | | 2/27/2018 | 140 | Influenza, split virus, trivalent, PF | CSL |
| 33332-0013-01 | AFLURIA | CSL Limited | 7/1/2013 | 6/30/2014 | | 7/13/2018 | 33332-0013-02 | False | | 11/20/2017 | 140 | Influenza, split virus, trivalent, PF | CSL |
| 33332-0014-01 | AFLURIA | CSL Limited | 7/15/2014 | 6/30/2015 | | 12/7/2017 | 33332-0014-02 | False | | 7/3/2018 | 140 | Influenza, split virus, trivalent, PF | CSL |
| 33332-0015-01 | AFLURIA | bioCSL Pty Ltd. | 7/1/2015 | 6/30/2016 | | 10/8/2019 | 33332-0015-02 | False | | 10/8/2019 | 140 | Influenza, split virus, trivalent, PF | CSL |
| 33332-0016-01 | AFLURIA | Seqirus Pty Ltd | 7/1/2016 | 6/30/2017 | | 7/11/2018 | 33332-0016-02 | False | | 7/3/2018 | 140 | Influenza, split virus, trivalent, PF | SEQ |
| 33332-0017-01 | AFLURIA | Seqirus Pty Ltd | 7/1/2017 | 6/30/2018 | | 8/13/2018 | 33332-0017-02 | False | | 8/13/2018 | 140 | Influenza, split virus, trivalent, PF | SEQ |
| 33332-0018-01 | AFLURIA | Seqirus Pty Ltd | 7/1/2018 | 12/20/2019 | | 1/21/2020 | 33332-0018-02 | False | | 1/21/2020 | 140 | Influenza, split virus, trivalent, PF | SEQ |
| 33332-0024-03 | Afluria | Seqirus PTY LTD. | 7/1/2024 | 6/30/2025 | 00333332024032 | 7/16/2025 | 33332-0024-04 | False | 00333332024049 | 7/16/2025 | 140 | Influenza, split virus, trivalent, PF | SEQ |
| 33332-0025-03 | Afluria | Seqirus PTY LTD. | 7/1/2025 | | 00333332025039 | 11/13/2025 | 33332-0025-04 | False | 00333332025046 | 11/13/2025 | 140 | Influenza, split virus, trivalent, PF | SEQ |
| 33332-0110-10 | AFLURIA | CSL Limited | 7/30/2010 | 6/30/2011 | | 1/29/2018 | 33332-0110-10 | True | | 1/29/2018 | 141 | Influenza, split virus, trivalent, preservative | CSL |
| 33332-0113-10 | AFLURIA | CSL Limited | 7/1/2013 | 6/30/2014 | | 7/13/2018 | 33332-0113-11 | False | | 7/3/2018 | 141 | Influenza, split virus, trivalent, preservative | CSL |
| 33332-0114-10 | AFLURIA | CSL Limited | 7/15/2014 | 6/30/2015 | | 7/13/2018 | 33332-0114-11 | False | | 7/3/2018 | 141 | Influenza, split virus, trivalent, preservative | CSL |
| 33332-0115-10 | AFLURIA | bioCSL Pty Ltd. | 7/1/2015 | 6/30/2016 | | 10/8/2019 | 33332-0115-11 | False | | 10/8/2019 | 141 | Influenza, split virus, trivalent, preservative | CSL |
| 33332-0116-10 | AFLURIA | Seqirus Pty Ltd | 7/1/2016 | 6/30/2017 | | 7/11/2018 | 33332-0116-11 | False | | 7/3/2018 | 141 | Influenza, split virus, trivalent, preservative | SEQ |
| 33332-0117-10 | AFLURIA | Seqirus Pty Ltd | 7/1/2017 | 6/30/2018 | | 8/13/2018 | 33332-0117-11 | False | | 8/13/2018 | 141 | Influenza, split virus, trivalent, preservative | SEQ |
| 33332-0118-10 | AFLURIA | Seqirus Pty Ltd | 7/1/2018 | 12/20/2019 | | 1/21/2020 | 33332-0118-11 | False | | 1/21/2020 | 141 | Influenza, split virus, trivalent, preservative | SEQ |
| 33332-0124-10 | Afluria | Seqirus PTY LTD. | 7/1/2024 | 6/30/2025 | 00333332124107 | 7/16/2025 | 33332-0124-11 | False | 00333332124114 | 7/16/2025 | 141 | Influenza, split virus, trivalent, preservative | SEQ |
| 33332-0125-10 | Afluria | Seqirus PTY LTD. | 7/1/2025 | | 00333332125104 | 11/13/2025 | 33332-0125-11 | False | 00333332125111 | 11/13/2025 | 141 | Influenza, split virus, trivalent, preservative | SEQ |
| 33332-0219-20 | Afluria Quadrivalent | Seqirus Pty Ltd. | 7/2/2019 | 7/31/2020 | 00333332219209 | 7/18/2024 | 33332-0219-21 | False | 00333332219216 | 7/18/2024 | 161 | Influenza, injectable,quadrivalent, preservative free, pediatric | SEQ |
| 33332-0220-20 | Afluria Quadrivalent | Seqirus Pty Ltd. | 7/2/2020 | 7/1/2021 | | 7/18/2024 | 33332-0220-21 | False | | 7/18/2024 | 161 | Influenza, injectable,quadrivalent, preservative free, pediatric | SEQ |
| 33332-0221-20 | Afluria Quadrivalent | Seqirus PTY LTD. | 7/2/2021 | 6/30/2022 | | 7/18/2024 | 33332-0221-21 | False | | 7/18/2024 | 161 | Influenza, injectable,quadrivalent, preservative free, pediatric | SEQ |
| 33332-0316-01 | AFLURIA QUADRIVALENT | Seqirus | 7/1/2016 | 6/30/2017 | | 7/13/2018 | 33332-0316-02 | False | | 7/3/2018 | 150 | Influenza, split virus, quadrivalent, PF | SEQ |
| 33332-0317-01 | AFLURIA QUADRIVALENT | Seqirus Pty Ltd | 7/1/2017 | 6/30/2018 | | 8/13/2018 | 33332-0317-02 | False | | 8/13/2018 | 150 | Influenza, split virus, quadrivalent, PF | SEQ |
| 33332-0318-01 | AFLURIA QUADRIVALENT | Seqirus Pty Ltd | 7/1/2018 | 6/30/2019 | | 12/20/2019 | 33332-0318-02 | False | | 12/20/2019 | 150 | Influenza, split virus, quadrivalent, PF | SEQ |
| 33332-0319-01 | Afluria Quadrivalent | Seqirus Pty Ltd. | 7/1/2019 | 7/31/2020 | 00333332319015 | 7/18/2024 | 33332-0319-02 | False | 00333332319022 | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | SEQ |
| 33332-0320-01 | Afluria Quadrivalent | Seqirus Pty Ltd. | 7/2/2020 | 7/1/2021 | | 7/18/2024 | 33332-0320-02 | False | | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | SEQ |
| 33332-0321-01 | Afluria Quadrivalent | Seqirus PTY LTD. | 7/2/2021 | 6/30/2022 | | 7/18/2024 | 33332-0321-02 | False | | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | SEQ |
| 33332-0322-03 | Afluria Quadrivalent | Seqirus PTY LTD. | 7/1/2022 | 6/30/2023 | 00333332322039 | 7/18/2024 | 33332-0322-04 | False | 00333332322046 | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | SEQ |
| 33332-0323-03 | Afluria Quadrivalent | Seqirus PTY LTD. | 7/1/2023 | 6/30/2024 | 00333332323036 | 8/6/2024 | 33332-0323-04 | False | 00333332323043 | 8/6/2024 | 150 | Influenza, split virus, quadrivalent, PF | SEQ |
| 33332-0416-10 | AFLURIA QUADRIVALENT | Seqirus | 7/1/2016 | 6/30/2017 | | 7/13/2018 | 33332-0416-11 | False | | 7/3/2018 | 158 | Influenza, split virus, quadrivalent, preservative | SEQ |
| 33332-0417-10 | AFLURIA QUADRIVALENT | Seqirus Pty Ltd | 8/16/2017 | 6/30/2018 | | 8/13/2018 | 33332-0417-11 | False | | 8/13/2018 | 158 | Influenza, split virus, quadrivalent, preservative | SEQ |
| 33332-0418-10 | AFLURIA QUADRIVALENT | Seqirus Pty Ltd | 7/1/2018 | 6/30/2019 | | 12/20/2019 | 33332-0418-11 | False | | 12/20/2019 | 158 | Influenza, split virus, quadrivalent, preservative | SEQ |
| 33332-0419-10 | Afluria Quadrivalent | Seqirus Pty Ltd. | 7/1/2019 | 7/31/2020 | 00333332419104 | 7/18/2024 | 33332-0419-11 | False | 00333332419111 | 7/18/2024 | 158 | Influenza, split virus, quadrivalent, preservative | SEQ |
| 33332-0420-10 | Afluria Quadrivalent | Seqirus Pty Ltd. | 7/2/2020 | 7/1/2021 | | 7/18/2024 | 33332-0420-11 | False | | 3/6/2025 | 158 | Influenza, split virus, quadrivalent, preservative | SEQ |
| 33332-0421-10 | Afluria Quadrivalent | Seqirus PTY LTD. | 7/2/2021 | 6/30/2022 | | 7/18/2024 | 33332-0421-11 | False | | 7/18/2024 | 158 | Influenza, split virus, quadrivalent, preservative | SEQ |
| 33332-0422-10 | Afluria Quadrivalent | Seqirus PTY LTD. | 7/1/2022 | 6/30/2023 | | 7/18/2024 | 33332-0422-11 | False | 00333332422111 | 7/18/2024 | 158 | Influenza, split virus, quadrivalent, preservative | SEQ |
| 33332-0423-10 | Afluria Quadrivalent | Seqirus PTY LTD. | 7/1/2023 | 6/30/2024 | 00333332423101 | 8/6/2024 | 33332-0423-11 | False | 00333332423118 | 8/6/2024 | 158 | Influenza, split virus, quadrivalent, preservative | SEQ |
| 33332-0519-01 | Influenza A | CSL Limited | 7/1/2009 | 6/30/2010 | | 1/29/2018 | 33332-0519-01 | True | | 1/29/2018 | 126 | Novel influenza-H1N1-09, preservative-free | CSL |
| 33332-0519-25 | Influenza A | CSL Limited | 7/1/2009 | 6/30/2010 | | 1/29/2018 | 33332-0519-25 | True | | 1/29/2018 | 126 | Novel influenza-H1N1-09, preservative-free | CSL |
| 33332-0629-10 | Influenza A | CSL Limited | 7/1/2009 | 6/30/2010 | | 1/29/2018 | 33332-0629-10 | True | | 1/29/2018 | 127 | Novel influenza-H1N1-09 | CSL |
| 42515-0001-01 | IXIARO | Valneva Scotland Ltd. | 3/30/2009 | 2/13/2018 | | 3/7/2023 | 42515-0001-00 | False | | 3/7/2023 | 134 | Japanese Encephalitis IM | VAL |
| 42515-0001-01 | IXIARO | Valneva Scotland Ltd. | 3/30/2009 | 2/13/2018 | | 3/7/2023 | 42515-0001-00 | False | | 3/7/2023 | 134 | Japanese Encephalitis IM | INT |
| 42515-0001-01 | IXIARO | Valneva Scotland Ltd. | 3/30/2009 | 2/13/2018 | | 3/7/2023 | 42515-0001-01 | True | | 10/15/2019 | 134 | Japanese Encephalitis IM | VAL |
| 42515-0001-01 | IXIARO | Valneva Scotland Ltd. | 3/30/2009 | 2/13/2018 | | 3/7/2023 | 42515-0001-01 | True | | 10/15/2019 | 134 | Japanese Encephalitis IM | INT |
| 42515-0002-01 | IXIARO | Valneva Scotland Ltd. | 3/30/2009 | | | 7/12/2018 | 42515-0002-01 | True | | 4/6/2018 | 134 | Japanese Encephalitis IM | VAL |
| 42515-0003-01 | IXCHIQ | Valneva Scotland Ltd. | 1/15/2024 | | 00342515003016 | 9/15/2025 | 42515-0003-00 | False | | 9/15/2025 | 317 | Chikungunya live attenuated vaccine, 0.5 mL, PF | VAL |
| 42874-0012-10 | Flublok | Protein Sciences Corporation | 2/1/2013 | 6/30/2013 | | 10/8/2019 | 42874-0012-01 | False | | 10/8/2019 | 155 | Influenza, recombinant, trivalent, PF | PSC |
| 42874-0013-10 | Flublok | Protein Sciences Corporation | 11/1/2013 | 6/30/2014 | | 10/8/2019 | 42874-0013-01 | False | | 10/8/2019 | 155 | Influenza, recombinant, trivalent, PF | PSC |
| 42874-0014-10 | Flublok | Protein Sciences Corporation | 9/15/2014 | 6/30/2015 | | 10/8/2019 | 42874-0014-01 | False | | 10/8/2019 | 155 | Influenza, recombinant, trivalent, PF | PSC |
| 42874-0015-10 | Flublok | Protein Sciences Corporation | 8/7/2015 | 6/30/2016 | | 10/8/2019 | 42874-0015-01 | False | | 10/8/2019 | 155 | Influenza, recombinant, trivalent, PF | PSC |
| 42874-0016-10 | Flublok | Protein Sciences Corporation | 8/1/2016 | 6/30/2017 | | 10/8/2019 | 42874-0016-01 | False | | 10/8/2019 | 155 | Influenza, recombinant, trivalent, PF | PSC |
| 42874-0017-10 | Flublok | Protein Sciences Corporation | 7/14/2017 | 6/30/2018 | | 10/8/2019 | 42874-0017-01 | False | | 10/8/2019 | 155 | Influenza, recombinant, trivalent, PF | PSC |
| 42874-0117-10 | Flublok Quadrivalent | Protein Sciences Corporation | 7/14/2017 | 6/30/2018 | | 7/9/2018 | 42874-0117-01 | False | | 7/9/2018 | 185 | Influenza, recombinant, quadrivalent, PF | PSC |
| 43528-0002-05 | HEPLISAV-B | Dynavax Technologies Corporation | 1/1/2018 | 12/20/2019 | 00343528002058 | 1/21/2020 | 43528-0002-01 | False | 00343528002010 | 1/21/2020 | 189 | HepB-CpG | DVX |
| 43528-0003-05 | HEPLISAV-B | Dynavax Technologies Corporation | 1/1/2018 | | 00343528003055 | 2/24/2026 | 43528-0003-01 | False | 00343528003017 | 2/24/2026 | 189 | HepB-CpG | DVX |
| 46028-0114-01 | Bexsero | Novartis Vaccines and Diagnostics SRL | 1/23/2015 | 10/31/2017 | | 5/30/2018 | 46028-0114-11 | False | | 5/30/2018 | 163 | meningococcal B, OMV | NOV |
| 46028-0114-02 | Bexsero | Novartis Vaccines and Diagnostics SRL | 1/23/2015 | 10/31/2017 | | 5/30/2018 | 46028-0114-11 | False | | 5/30/2018 | 163 | meningococcal B, OMV | NOV |
| 46028-0208-01 | Menveo | Novartis Vaccines and Diagnostics s.r.l. | 2/19/2010 | 4/30/2018 | | 12/16/2022 | 46028-0219-11 | False | 00346028219117 | 5/16/2018 | 136 | Meningococcal MCV4O | NOV |
| 46028-0208-01 | Menveo | Novartis Vaccines and Diagnostics s.r.l. | 2/19/2010 | 4/30/2018 | | 12/16/2022 | 46028-0218-11 | False | 00346028218110 | 5/16/2018 | 136 | Meningococcal MCV4O | NOV |
| 49281-0010-10 | FLUZONE | Sanofi Pasteur Inc. | 7/23/2010 | 6/30/2011 | | 1/29/2018 | 49281-0010-10 | True | 00349281010101 | 7/4/2018 | 140 | Influenza, split virus, trivalent, PF | PMC |
| 49281-0010-25 | FLUZONE | Sanofi Pasteur Inc. | 7/23/2010 | 6/30/2011 | | 1/29/2018 | 49281-0010-25 | True | 00349281010255 | 9/19/2018 | 140 | Influenza, split virus, trivalent, PF | PMC |
| 49281-0010-50 | FLUZONE | Sanofi Pasteur Inc. | 7/23/2010 | 6/30/2011 | | 1/29/2018 | 49281-0010-50 | True | 00349281010507 | 7/4/2018 | 140 | Influenza, split virus, trivalent, PF | PMC |
| 49281-0011-10 | FLUZONE | Sanofi Pasteur Inc. | 7/1/2011 | 6/30/2012 | | 1/29/2018 | 49281-0011-10 | True | 00349281011108 | 2/13/2018 | 140 | Influenza, split virus, trivalent, PF | PMC |
| 49281-0011-50 | FLUZONE | Sanofi Pasteur Inc. | 7/1/2011 | 6/30/2012 | | 1/29/2018 | 49281-0011-50 | True | 00349281011504 | 1/29/2018 | 140 | Influenza, split virus, trivalent, PF | PMC |
| 49281-0012-10 | FLUZONE | Sanofi Pasteur Inc. | 7/2/2012 | 6/30/2013 | | 12/7/2017 | 49281-0012-10 | True | 00349281012105 | 7/4/2018 | 140 | Influenza, split virus, trivalent, PF | PMC |
| 49281-0012-50 | FLUZONE | Sanofi Pasteur Inc. | 7/2/2012 | 6/30/2013 | | 12/7/2017 | 49281-0012-50 | True | 00349281012501 | 11/20/2017 | 140 | Influenza, split virus, trivalent, PF | PMC |
| 49281-0013-10 | FLUZONE | Sanofi Pasteur Inc. | 6/28/2013 | 6/30/2014 | | 12/7/2017 | 49281-0013-58 | False | 00349281013584 | 11/20/2017 | 140 | Influenza, split virus, trivalent, PF | PMC |
| 49281-0013-50 | FLUZONE | Sanofi Pasteur Inc. | 6/28/2013 | 6/30/2014 | | 12/7/2017 | 49281-0013-88 | False | 00349281013881 | 11/20/2017 | 140 | Influenza, split virus, trivalent, PF | PMC |
| 49281-0014-50 | FLUZONE | Sanofi Pasteur Inc. | 6/27/2014 | 6/30/2015 | | 7/6/2018 | 49281-0014-88 | False | 00349281014888 | 7/4/2018 | 140 | Influenza, split virus, trivalent, PF | PMC |
| 49281-0016-50 | FLUZONE HD TIV SH 2026 | Sanofi Vaccines US Inc. | 2/20/2026 | | | 4/14/2026 | 49281-0016-88 | False | | 4/8/2026 | 337 | Influenza, Southern Hemisphere, high-dose, trivalent, PF | PMC |
| 49281-0111-25 | FLUZONE | Sanofi Pasteur Inc. | 7/1/2011 | 6/30/2012 | | 1/29/2018 | 49281-0111-25 | True | 00349281111259 | 7/4/2018 | 140 | Influenza, split virus, trivalent, PF | PMC |
| 49281-0112-25 | FLUZONE | Sanofi Pasteur Inc. | 7/2/2012 | 6/30/2013 | | 12/7/2017 | 49281-0112-25 | True | 00349281112256 | 7/4/2018 | 140 | Influenza, split virus, trivalent, PF | PMC |
| 49281-0113-25 | FLUZONE | Sanofi Pasteur Inc. | 6/28/2013 | 6/30/2014 | | 12/7/2017 | 49281-0113-00 | False | 00349281113000 | 11/20/2017 | 140 | Influenza, split virus, trivalent, PF | PMC |
| 49281-0120-65 | FLUZONE High-Dose Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 11/1/2019 | 6/30/2021 | | 7/18/2024 | 49281-0120-88 | False | | 7/18/2024 | 197 | Influenza, high-dose, quadrivalent, PF | PMC |
| 49281-0121-65 | FLUZONE High-Dose Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 7/2/2021 | 6/30/2022 | 00349281121654 | 7/18/2024 | 49281-0121-88 | False | 00349281121883 | 7/18/2024 | 197 | Influenza, high-dose, quadrivalent, PF | PMC |
| 49281-0122-65 | FLUZONE High-Dose Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 7/1/2022 | 6/30/2023 | 00349281122651 | 7/18/2024 | 49281-0122-88 | False | 00349281122880 | 7/18/2024 | 197 | Influenza, high-dose, quadrivalent, PF | PMC |
| 49281-0123-65 | Fluzone High-Dose Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 6/30/2023 | 6/30/2024 | 00349281123658 | 9/19/2024 | 49281-0123-88 | False | 00349281123887 | 9/19/2024 | 197 | Influenza, high-dose, quadrivalent, PF | PMC |
| 49281-0124-65 | FLUZONE HIGH DOSE NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/1/2024 | 6/30/2025 | 00349281124655 | 7/16/2025 | 49281-0124-88 | False | 00349281124884 | 7/16/2025 | 135 | Influenza, high-dose, trivalent, PF | PMC |
| 49281-0125-65 | FLUZONE HIGH DOSE NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/1/2025 | | | 7/16/2025 | 49281-0125-88 | False | | 7/16/2025 | 135 | Influenza, high-dose, trivalent, PF | PMC |
| 49281-0181-25 | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 9/30/2019 | 12/31/2020 | | 7/18/2024 | 49281-0181-00 | False | | 7/18/2024 | 200 | influenza, Southern Hemisphere, pediatric, preservative free | PMC |
| 49281-0182-25 | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 2/4/2021 | 12/31/2021 | 00349281182259 | 7/18/2024 | 49281-0182-00 | False | 00349281182006 | 7/18/2024 | 200 | influenza, Southern Hemisphere, pediatric, preservative free | PMC |
| 49281-0215-10 | TENIVAC | Sanofi Vaccines US Inc. | 12/8/2010 | | 00349281215100 | 4/27/2026 | 49281-0215-58 | False | 00349281215582 | 4/27/2026 | 113 | Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed | PMC |
| 49281-0215-15 | TENIVAC | Sanofi Vaccines US Inc. | 12/8/2010 | | 00349281215155 | 4/27/2026 | 49281-0215-88 | False | 00349281215889 | 4/27/2026 | 113 | Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed | PMC |
| 49281-0225-10 | DIPHTHERIA AND TETANUS TOXOIDS ADSORBED | Sanofi Pasteur Inc. | 3/29/2010 | 4/30/2023 | 00349281225109 | 11/5/2024 | 49281-0225-58 | False | 00349281225581 | 11/5/2024 | 28 | DT (pediatric) | PMC |
| 49281-0250-51 | IMOVAX RABIES | Sanofi Pasteur Inc. | 9/30/2013 | 12/7/2021 | 00349281250514 | 12/13/2021 | 49281-0248-58 | False | 00349281248580 | 5/16/2022 | 175 | Rabies - IM Diploid cell culture | PMC |
| 49281-0252-51 | IMOVAX RABIES | Sanofi Vaccines US Inc. | 10/25/2019 | | 00349281252518 | 2/18/2026 | 49281-0246-58 | False | 00349281246586 | 2/18/2026 | 175 | Rabies - IM Diploid cell culture | PMC |
| 49281-0278-10 | DIPHTHERIA AND TETANUS TOXOIDS ADSORBED | Sanofi Pasteur Inc. | 9/18/1984 | 3/18/2013 | | 1/29/2018 | 49281-0278-10 | True | | 1/29/2018 | 28 | DT (pediatric) | PMC |
| 49281-0286-01 | DAPTACEL | Sanofi Vaccines US Inc. | 5/14/2002 | | 00349281286018 | 4/27/2026 | 49281-0286-58 | False | 00349281286582 | 4/27/2026 | 106 | DTaP, 5 pertussis antigens | PMC |
| 49281-0286-05 | DAPTACEL | Sanofi Vaccines US Inc. | 5/14/2002 | | 00349281286056 | 4/27/2026 | 49281-0286-58 | False | 00349281286582 | 4/27/2026 | 106 | DTaP, 5 pertussis antigens | PMC |
| 49281-0286-10 | DAPTACEL | Sanofi Vaccines US Inc. | 5/14/2002 | | 00349281286100 | 4/27/2026 | 49281-0286-58 | False | 00349281286582 | 4/27/2026 | 106 | DTaP, 5 pertussis antigens | PMC |
| 49281-0291-10 | DECAVAC | Sanofi Pasteur Inc. | 3/24/2004 | 12/31/2012 | | 5/30/2018 | 49281-0291-10 | True | | 5/30/2018 | 113 | Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed | PMC |
| 49281-0291-83 | DECAVAC | Sanofi Pasteur Inc. | 3/24/2004 | 12/31/2012 | | 5/30/2018 | 49281-0291-83 | True | | 6/8/2018 | 113 | Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed | PMC |
| 49281-0298-10 | TRIPEDIA | Sanofi Pasteur Inc. | 8/20/1992 | 3/13/2013 | | 1/29/2018 | 49281-0298-10 | True | | 1/29/2018 | 20 | DTaP | PMC |
| 49281-0320-50 | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 9/30/2019 | 12/31/2020 | | 7/18/2024 | 49281-0320-88 | False | | 7/18/2024 | 201 | Influenza, Southern Hemisphere, quadrivalent, PF | PMC |
| 49281-0321-50 | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 2/4/2021 | 12/31/2021 | 00349281321504 | 7/18/2024 | 49281-0321-88 | False | 00349281321887 | 7/18/2024 | 201 | Influenza, Southern Hemisphere, quadrivalent, PF | PMC |
| 49281-0322-50 | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 2/15/2022 | 12/31/2022 | 00349281322501 | 7/18/2024 | 49281-0322-88 | False | 00349281322884 | 7/18/2024 | 201 | Influenza, Southern Hemisphere, quadrivalent, PF | PMC |
| 49281-0323-50 | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 2/13/2023 | 12/31/2023 | | 7/18/2024 | 49281-0323-88 | False | | 7/18/2024 | 201 | Influenza, Southern Hemisphere, quadrivalent, PF | PMC |
| 49281-0324-50 | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 2/14/2024 | 12/31/2024 | 00349281324505 | 1/27/2025 | 49281-0324-88 | False | 00349281324888 | 1/24/2025 | 201 | Influenza, Southern Hemisphere, quadrivalent, PF | PMC |
| 49281-0325-50 | FLUZONE TRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 3/6/2025 | 12/31/2025 | | 1/8/2026 | 49281-0325-88 | False | | 1/8/2026 | 331 | Influenza, Southern Hemisphere, trivalent, PF | PMC |
| 49281-0336-15 | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 9/30/2019 | 12/31/2020 | | 7/18/2024 | 49281-0336-78 | False | | 7/18/2024 | 202 | influenza, Southern Hemisphere, quadrivalent, with preservative | PMC |
| 49281-0337-15 | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 2/4/2021 | 12/31/2021 | 00349281337154 | 7/18/2024 | 49281-0337-78 | False | 00349281337789 | 7/18/2024 | 202 | influenza, Southern Hemisphere, quadrivalent, with preservative | PMC |
| 49281-0339-15 | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 2/15/2022 | 12/31/2022 | 00349281339158 | 7/18/2024 | 49281-0339-78 | False | 00349281339783 | 7/18/2024 | 202 | influenza, Southern Hemisphere, quadrivalent, with preservative | PMC |
| 49281-0355-15 | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 2/13/2023 | 12/31/2023 | | 7/18/2024 | 49281-0355-78 | False | | 7/18/2024 | 202 | influenza, Southern Hemisphere, quadrivalent, with preservative | PMC |
| 49281-0379-50 | FLUZONE High-Dose Quadrivalent Southern Hemisphere | Sanofi Pasteur Inc. | 2/13/2023 | 12/31/2023 | | 7/18/2024 | 49281-0379-88 | False | | 7/18/2024 | 231 | influenza, Southern Hemisphere, high-dose, quadrivalent | PMC |
| 49281-0386-15 | FLUZONE | Sanofi Pasteur Inc. | 7/23/2010 | 6/30/2011 | | 1/29/2018 | 49281-0386-15 | True | 00349281386152 | 7/4/2018 | 141 | Influenza, split virus, trivalent, preservative | PMC |
| 49281-0387-65 | FLUZONE | Sanofi Pasteur Inc. | 7/23/2010 | 6/30/2011 | | 1/29/2018 | 49281-0387-65 | True | 00349281387654 | 7/4/2018 | 135 | Influenza, high-dose, trivalent, PF | PMC |
| 49281-0388-15 | FLUZONE | Sanofi Pasteur Inc. | 7/1/2011 | 6/30/2012 | | 1/29/2018 | 49281-0388-15 | True | 00349281388156 | 1/29/2018 | 141 | Influenza, split virus, trivalent, preservative | PMC |
| 49281-0389-65 | FLUZONE HIGH DOSE | Sanofi Pasteur Inc. | 7/1/2011 | 6/30/2012 | | 2/27/2018 | 49281-0389-65 | True | 00349281389658 | 7/4/2018 | 135 | Influenza, high-dose, trivalent, PF | PMC |
| 49281-0390-15 | FLUZONE | Sanofi Pasteur Inc. | 7/2/2012 | 6/30/2013 | | 12/7/2017 | 49281-0390-15 | True | 00349281390159 | 7/4/2018 | 141 | Influenza, split virus, trivalent, preservative | PMC |
| 49281-0391-65 | FLUZONE High-Dose | Sanofi Pasteur Inc. | 7/2/2012 | 6/30/2013 | | 12/7/2017 | 49281-0391-65 | True | 00349281391651 | 7/4/2018 | 135 | Influenza, high-dose, trivalent, PF | PMC |
| 49281-0392-15 | FLUZONE | Sanofi Pasteur Inc. | 6/28/2013 | 6/30/2014 | | 12/7/2017 | 49281-0392-78 | False | 00349281392788 | 11/20/2017 | 141 | Influenza, split virus, trivalent, preservative | PMC |
| 49281-0393-65 | FLUZONE High-Dose | Sanofi Pasteur Inc. | 6/28/2013 | 6/30/2014 | | 12/7/2017 | 49281-0393-88 | False | 00349281393884 | 11/20/2017 | 135 | Influenza, high-dose, trivalent, PF | PMC |
| 49281-0394-15 | FLUZONE | Sanofi Pasteur Inc. | 6/27/2014 | 6/30/2015 | | 7/6/2018 | 49281-0394-78 | False | | 7/4/2018 | 141 | Influenza, split virus, trivalent, preservative | PMC |
| 49281-0395-65 | FLUZONE High-Dose | Sanofi Pasteur Inc. | 6/27/2014 | 6/30/2015 | | 6/27/2018 | 49281-0395-88 | False | | 7/4/2018 | 135 | Influenza, high-dose, trivalent, PF | PMC |
| 49281-0396-15 | FLUZONE | Sanofi Pasteur Inc. | 6/26/2015 | 6/30/2016 | | 12/7/2017 | 49281-0396-78 | False | 00349281396786 | 11/20/2017 | 141 | Influenza, split virus, trivalent, preservative | PMC |
| 49281-0397-65 | FLUZONE High-Dose | Sanofi Pasteur Inc. | 6/26/2015 | 6/30/2016 | | 12/7/2017 | 49281-0397-88 | False | 00349281397882 | 11/20/2017 | 135 | Influenza, high-dose, trivalent, PF | PMC |
| 49281-0398-15 | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 2/14/2024 | 12/31/2024 | | 1/27/2025 | 49281-0398-78 | False | | 1/24/2025 | 202 | influenza, Southern Hemisphere, quadrivalent, with preservative | PMC |
| 49281-0399-65 | FLUZONE High-Dose | Sanofi Pasteur Inc. | 7/1/2016 | 6/30/2017 | | 7/11/2018 | 49281-0399-88 | False | | 5/30/2018 | 135 | Influenza, high-dose, trivalent, PF | PMC |
| 49281-0400-05 | Adacel | Sanofi Vaccines US Inc. | 6/10/2005 | | 00349281400056 | 4/27/2026 | 49281-0400-58 | False | 00349281400582 | 4/27/2026 | 115 | Tdap | PMC |
| 49281-0400-10 | Adacel | Sanofi Vaccines US Inc. | 6/10/2005 | | 00349281400100 | 4/27/2026 | 49281-0400-58 | False | 00349281400582 | 4/27/2026 | 115 | Tdap | PMC |
| 49281-0400-15 | Adacel | Sanofi Pasteur Inc. | 10/1/2013 | 1/20/2021 | | 1/28/2021 | 49281-0400-88 | False | 00349281400889 | 1/25/2021 | 115 | Tdap | PMC |
| 49281-0400-20 | Adacel | Sanofi Vaccines US Inc. | 6/10/2005 | | 00349281400209 | 4/27/2026 | 49281-0400-89 | False | 00349281400896 | 4/27/2026 | 115 | Tdap | PMC |
| 49281-0401-65 | FLUZONE High-Dose | Sanofi Pasteur Inc. | 7/1/2017 | 6/30/2018 | | 7/9/2018 | 49281-0401-88 | False | | 7/9/2018 | 135 | Influenza, high-dose, trivalent, PF | PMC |
| 49281-0403-65 | FLUZONE High-Dose | Sanofi Pasteur Inc. | 6/29/2018 | 6/30/2019 | | 1/21/2025 | 49281-0403-88 | False | 00349281403880 | 1/21/2025 | 135 | Influenza, high-dose, trivalent, PF | PMC |
| 49281-0405-65 | FLUZONE High-Dose | Sanofi Pasteur Inc. | 7/1/2019 | 6/30/2020 | | 1/21/2025 | 49281-0405-88 | False | 00349281405884 | 1/21/2025 | 135 | Influenza, high-dose, trivalent, PF | PMC |
| 49281-0413-10 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 6/10/2013 | 6/30/2014 | | 12/7/2017 | 49281-0413-58 | False | 00349281413582 | 11/20/2017 | 150 | Influenza, split virus, quadrivalent, PF | PMC |
| 49281-0413-50 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 6/10/2013 | 6/30/2014 | | 12/7/2017 | 49281-0413-88 | False | 00349281413889 | 11/20/2017 | 150 | Influenza, split virus, quadrivalent, PF | PMC |
| 49281-0414-10 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 6/27/2014 | 6/30/2015 | | 7/13/2018 | 49281-0414-58 | False | 00349281414589 | 7/5/2018 | 150 | Influenza, split virus, quadrivalent, PF | PMC |
| 49281-0414-50 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 6/27/2014 | 6/30/2015 | | 7/12/2018 | 49281-0414-88 | False | 00349281414886 | 7/5/2018 | 150 | Influenza, split virus, quadrivalent, PF | PMC |
| 49281-0415-10 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 6/26/2015 | 6/30/2016 | | 7/12/2018 | 49281-0415-58 | False | 00349281415586 | 5/30/2018 | 150 | Influenza, split virus, quadrivalent, PF | PMC |
| 49281-0416-10 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2016 | 6/30/2017 | | 7/11/2018 | 49281-0416-58 | False | | 5/30/2018 | 150 | Influenza, split virus, quadrivalent, PF | PMC |
| 49281-0416-50 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2016 | 6/30/2017 | | 7/11/2018 | 49281-0416-88 | False | | 5/30/2018 | 150 | Influenza, split virus, quadrivalent, PF | PMC |
| 49281-0417-10 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2017 | 6/30/2018 | | 7/13/2018 | 49281-0417-58 | False | 00349281417580 | 7/9/2018 | 150 | Influenza, split virus, quadrivalent, PF | PMC |
| 49281-0417-50 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2017 | 6/30/2018 | | 7/13/2018 | 49281-0417-88 | False | 00349281417887 | 7/9/2018 | 150 | Influenza, split virus, quadrivalent, PF | PMC |
| 49281-0418-10 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 6/29/2018 | 6/30/2019 | | 7/16/2019 | 49281-0418-58 | False | 00349281418587 | 7/16/2019 | 150 | Influenza, split virus, quadrivalent, PF | PMC |
| 49281-0418-50 | FLUZONE QUADRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 6/29/2018 | 6/30/2019 | | 8/6/2024 | 49281-0418-88 | False | 00349281418884 | 8/6/2024 | 150 | Influenza, split virus, quadrivalent, PF | PMC |
| 49281-0419-10 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2019 | 6/30/2020 | | 7/18/2024 | 49281-0419-58 | False | 00349281419584 | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | PMC |
| 49281-0419-50 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2019 | 6/30/2020 | | 7/18/2024 | 49281-0419-88 | False | 00349281419881 | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | PMC |
| 49281-0420-10 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2020 | 6/30/2021 | | 7/18/2024 | 49281-0420-58 | False | | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | PMC |
| 49281-0420-50 | FLUZONE QUADRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/1/2020 | 6/30/2021 | | 8/6/2024 | 49281-0420-88 | False | | 8/6/2024 | 150 | Influenza, split virus, quadrivalent, PF | PMC |
| 49281-0421-10 | FLUZONE QUADRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/1/2021 | 6/30/2022 | 00349281421105 | 8/6/2024 | 49281-0421-58 | False | 00349281421587 | 8/6/2024 | 150 | Influenza, split virus, quadrivalent, PF | PMC |
| 49281-0421-50 | FLUZONE QUADRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/2/2021 | 6/30/2022 | 00349281421501 | 8/6/2024 | 49281-0421-88 | False | 00349281421884 | 8/6/2024 | 150 | Influenza, split virus, quadrivalent, PF | PMC |
| 49281-0422-10 | FLUZONE QUADRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/1/2022 | 6/30/2023 | 00349281422102 | 8/6/2024 | 49281-0422-58 | False | 00349281422584 | 8/6/2024 | 150 | Influenza, split virus, quadrivalent, PF | PMC |
| 49281-0422-50 | FLUZONE QUADRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/1/2022 | 6/30/2023 | 00349281422508 | 8/6/2024 | 49281-0422-88 | False | 00349281422881 | 8/6/2024 | 150 | Influenza, split virus, quadrivalent, PF | PMC |
| 49281-0423-50 | Fluzone Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 6/30/2023 | 6/30/2024 | 00349281423505 | 9/19/2024 | 49281-0423-88 | False | 00349281423888 | 9/19/2024 | 150 | Influenza, split virus, quadrivalent, PF | PMC |
| 49281-0424-50 | FLUZONE TRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/1/2024 | 6/30/2025 | 00349281424502 | 7/16/2025 | 49281-0424-88 | False | 00349281424885 | 7/15/2025 | 140 | Influenza, split virus, trivalent, PF | PMC |
| 49281-0425-50 | FLUZONE TRIVALENT NORTHERN HEMISPHERE | Sanofi Vaccines US Inc. | 7/1/2025 | | | 4/14/2026 | 49281-0425-88 | False | | 4/2/2026 | 140 | Influenza, split virus, trivalent, PF | PMC |
| 49281-0489-01 | MENOMUNE - A/C/Y/W-135 COMBINED | Sanofi Pasteur Inc. | 11/23/1981 | 4/30/2019 | | 5/29/2019 | 49281-0487-58 | False | 00349281487583 | 5/21/2019 | 32 | meningococcal MPSV4 | PMC |
| 49281-0489-91 | MENOMUNE - A/C/Y/W-135 COMBINED | Sanofi Pasteur Inc. | 11/23/1981 | 9/30/2017 | | 7/12/2018 | 49281-0488-78 | False | 00349281488788 | 5/21/2019 | 32 | meningococcal MPSV4 | PMC |
| 49281-0510-05 | PENTACEL | Sanofi Pasteur Inc. | 6/20/2008 | 11/9/2022 | 00349281510052 | 11/29/2022 | 49281-0548-58 | False | 00349281548581 | 11/29/2022 | 120 | DTaP-Hib-IPV | PMC |
| 49281-0510-05 | PENTACEL | Sanofi Pasteur Inc. | 6/20/2008 | 11/9/2022 | 00349281510052 | 11/29/2022 | 49281-0560-05 | False | 00349281560057 | 11/29/2022 | 120 | DTaP-Hib-IPV | PMC |
| 49281-0510-05 | PENTACEL | Sanofi Pasteur Inc. | 6/20/2008 | 11/9/2022 | 00349281510052 | 11/29/2022 | 49281-0545-15 | False | 00349281545153 | 8/22/2019 | 120 | DTaP-Hib-IPV | PMC |
| 49281-0511-05 | PENTACEL | Sanofi Vaccines US Inc. | 1/1/2020 | | 00349281511059 | 4/27/2026 | 49281-0561-01 | False | 00349281561016 | 4/27/2026 | 120 | DTaP-Hib-IPV | PMC |
| 49281-0511-05 | PENTACEL | Sanofi Vaccines US Inc. | 1/1/2020 | | 00349281511059 | 4/27/2026 | 49281-0544-58 | False | 00349281544583 | 4/27/2026 | 120 | DTaP-Hib-IPV | PMC |
| 49281-0513-25 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 6/10/2013 | 6/30/2014 | | 12/7/2017 | 49281-0513-00 | False | 00349281513008 | 11/20/2017 | 161 | Influenza, injectable,quadrivalent, preservative free, pediatric | PMC |
| 49281-0514-25 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 6/27/2014 | 6/30/2015 | | 7/13/2018 | 49281-0514-00 | False | 00349281514005 | 7/5/2018 | 161 | Influenza, injectable,quadrivalent, preservative free, pediatric | PMC |
| 49281-0516-25 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2016 | 6/30/2017 | | 7/11/2018 | 49281-0516-00 | False | | 5/30/2018 | 161 | Influenza, injectable,quadrivalent, preservative free, pediatric | PMC |
| 49281-0517-25 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2017 | 6/30/2018 | | 7/13/2018 | 49281-0517-00 | False | 00349281517006 | 7/9/2018 | 161 | Influenza, injectable,quadrivalent, preservative free, pediatric | PMC |
| 49281-0518-25 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 6/29/2018 | 6/30/2019 | | 7/16/2019 | 49281-0518-00 | False | 00349281518003 | 7/16/2019 | 161 | Influenza, injectable,quadrivalent, preservative free, pediatric | PMC |
| 49281-0519-25 | FLUZONE QUADRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/1/2019 | 6/30/2020 | | 8/6/2024 | 49281-0519-00 | False | 00349281519000 | 8/6/2024 | 161 | Influenza, injectable,quadrivalent, preservative free, pediatric | PMC |
| 49281-0520-25 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2020 | 6/30/2021 | | 7/18/2024 | 49281-0520-00 | False | | 7/18/2024 | 161 | Influenza, injectable,quadrivalent, preservative free, pediatric | PMC |
| 49281-0521-25 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 7/2/2021 | 6/30/2022 | 00349281521256 | 7/18/2024 | 49281-0521-00 | False | 00349281521003 | 7/18/2024 | 161 | Influenza, injectable,quadrivalent, preservative free, pediatric | PMC |
| 49281-0545-03 | ActHIB | Sanofi Vaccines US Inc. | 5/31/2016 | | 00349281545030 | 2/18/2026 | 49281-0547-58 | False | 00349281547584 | 2/18/2026 | 48 | Hib (PRP-T) | PMC |
| 49281-0545-05 | ActHIB | Sanofi Pasteur Inc. | 3/30/1993 | 11/28/2016 | | 7/12/2018 | 49281-0547-58 | False | 00349281547584 | 2/18/2026 | 48 | Hib (PRP-T) | PMC |
| 49281-0562-10 | QUADRACEL | Sanofi Pasteur Inc. | 3/24/2015 | 10/11/2024 | 00349281562105 | 10/16/2024 | 49281-0562-58 | False | 00349281562587 | 10/16/2024 | 130 | DTaP-IPV | PMC |
| 49281-0564-10 | QUADRACEL | Sanofi Vaccines US Inc. | 2/6/2020 | | 00349281564109 | 4/27/2026 | 49281-0564-58 | False | 00349281564581 | 4/27/2026 | 130 | DTaP-IPV | PMC |
| 49281-0564-15 | QUADRACEL | Sanofi Vaccines US Inc. | 2/4/2022 | | 00349281564154 | 4/27/2026 | 49281-0564-88 | False | 00349281564888 | 4/27/2026 | 130 | DTaP-IPV | PMC |
| 49281-0574-15 | BEYFORTUS | Sanofi Vaccines US Inc. | 7/18/2023 | | 00349281574153 | 4/27/2026 | 49281-0574-88 | False | 00349281574887 | 4/27/2026 | 307 | RSV, mAb, nirsevimab-alip, 1 mL, neonate to 24 months | PMC |
| 49281-0575-15 | BEYFORTUS | Sanofi Vaccines US Inc. | 7/18/2023 | | 00349281575150 | 4/27/2026 | 49281-0575-00 | False | 00349281575006 | 4/27/2026 | 306 | RSV, mAb, nirsevimab-alip, 0.5 mL, neonate to 24 months | PMC |
| 49281-0589-05 | Menactra | Sanofi Vaccines US Inc. | 1/14/2005 | 10/1/2022 | 00349281589058 | 3/3/2026 | 49281-0589-58 | False | 00349281589584 | 3/3/2026 | 114 | meningococcal MCV4P | PMC |
| 49281-0590-01 | MenQuadfi | Sanofi Vaccines US Inc. | 4/23/2020 | | 00349281590016 | 3/3/2026 | 49281-0590-58 | False | 00349281590580 | 3/3/2026 | 203 | meningococcal conjugate quadrivalent, MenACWY-TT (MCV4) | PMC |
| 49281-0590-05 | MenQuadfi | Sanofi Vaccines US Inc. | 4/23/2020 | | 00349281590054 | 3/3/2026 | 49281-0590-58 | False | 00349281590580 | 3/3/2026 | 203 | meningococcal conjugate quadrivalent, MenACWY-TT (MCV4) | PMC |
| 49281-0590-10 | MenQuadfi | Sanofi Vaccines US Inc. | 4/23/2020 | | | 3/3/2026 | 49281-0590-58 | False | 00349281590580 | 3/3/2026 | 203 | meningococcal conjugate quadrivalent, MenACWY-TT (MCV4) | PMC |
| 49281-0605-01 | Dengvaxia | Sanofi Vaccines US Inc. | 5/1/2019 | | 00349281605017 | 3/17/2026 | 49281-0606-58 | False | 00349281606588 | 3/17/2026 | 56 | dengue fever tetravalent | PMC |
| 49281-0618-20 | ANTIGEN COMPONENT | Sanofi Pasteur Inc. | 4/1/2022 | 10/31/2022 | | 1/10/2023 | 49281-0618-78 | False | | 1/10/2023 | 225 | COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL | PMC |
| 49281-0621-15 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 6/27/2014 | 6/30/2015 | | 7/6/2018 | 49281-0621-78 | False | | 11/20/2017 | 158 | Influenza, split virus, quadrivalent, preservative | PMC |
| 49281-0625-15 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2016 | 6/30/2017 | | 7/11/2018 | 49281-0625-78 | False | | 5/30/2018 | 158 | Influenza, split virus, quadrivalent, preservative | PMC |
| 49281-0626-50 | FLUZONE TIV SH 2026 | Sanofi Vaccines US Inc. | 2/20/2026 | | | 4/14/2026 | 49281-0626-88 | False | | 4/9/2026 | 331 | Influenza, Southern Hemisphere, trivalent, PF | PMC |
| 49281-0627-15 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2017 | 6/30/2018 | | 7/13/2018 | 49281-0627-78 | False | | 7/9/2018 | 158 | Influenza, split virus, quadrivalent, preservative | PMC |
| 49281-0629-15 | FLUZONE QUADRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 6/29/2018 | 6/30/2019 | | 8/6/2024 | 49281-0629-78 | False | 00349281629785 | 8/6/2024 | 158 | Influenza, split virus, quadrivalent, preservative | PMC |
| 49281-0631-15 | FLUZONE QUADRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/1/2019 | 6/30/2020 | | 8/6/2024 | 49281-0631-78 | False | 00349281631788 | 8/6/2024 | 158 | Influenza, split virus, quadrivalent, preservative | PMC |
| 49281-0633-15 | FLUZONE QUADRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/1/2020 | 6/30/2021 | | 8/6/2024 | 49281-0633-78 | False | | 8/6/2024 | 158 | Influenza, split virus, quadrivalent, preservative | PMC |
| 49281-0635-15 | FLUZONE QUADRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/2/2021 | 6/30/2022 | 00349281635151 | 8/6/2024 | 49281-0635-78 | False | 00349281635786 | 8/6/2024 | 158 | Influenza, split virus, quadrivalent, preservative | PMC |
| 49281-0637-15 | FLUZONE QUADRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/1/2022 | 6/30/2023 | 00349281637155 | 8/6/2024 | 49281-0637-78 | False | 00349281637780 | 8/6/2024 | 158 | Influenza, split virus, quadrivalent, preservative | PMC |
| 49281-0639-15 | Fluzone Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 6/30/2023 | 6/30/2024 | 00349281639159 | 9/19/2024 | 49281-0639-78 | False | 00349281639784 | 9/19/2024 | 158 | Influenza, split virus, quadrivalent, preservative | PMC |
| 49281-0640-15 | INFLUENZA A (H1N1) 2009 MONOVALENT VACCINE | Sanofi Pasteur Inc. | 9/15/2009 | 3/3/2017 | | 5/30/2018 | 49281-0640-15 | True | | 6/8/2018 | 127 | Novel influenza-H1N1-09 | PMC |
| 49281-0641-15 | FLUZONE TRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/1/2024 | 6/30/2025 | 00349281641152 | 7/16/2025 | 49281-0641-78 | False | 00349281641787 | 7/16/2025 | 141 | Influenza, split virus, trivalent, preservative | PMC |
| 49281-0643-15 | FLUZONE TRIVALENT NORTHERN HEMISPHERE | Sanofi Vaccines US Inc. | 7/1/2025 | | | 4/2/2026 | 49281-0643-78 | False | | 4/2/2026 | 141 | Influenza, split virus, trivalent, preservative | PMC |
| 49281-0650-10 | INFLUENZA A (H1N1) 2009 MONOVALENT VACCINE | Sanofi Pasteur Inc. | 9/15/2009 | 6/30/2010 | | 10/15/2019 | 49281-0650-10 | True | | 10/15/2019 | 126 | Novel influenza-H1N1-09, preservative-free | PMC |
| 49281-0650-25 | INFLUENZA A (H1N1) 2009 MONOVALENT VACCINE | Sanofi Pasteur Inc. | 9/15/2009 | 6/30/2010 | | 10/15/2019 | 49281-0650-25 | True | | 10/15/2019 | 126 | Novel influenza-H1N1-09, preservative-free | PMC |
| 49281-0650-50 | INFLUENZA A (H1N1) 2009 MONOVALENT VACCINE | Sanofi Pasteur Inc. | 9/15/2009 | 6/30/2010 | | 10/15/2019 | 49281-0650-50 | True | | 10/15/2019 | 126 | Novel influenza-H1N1-09, preservative-free | PMC |
| 49281-0650-70 | INFLUENZA A (H1N1) 2009 MONOVALENT VACCINE | Sanofi Pasteur Inc. | 9/15/2009 | 6/30/2010 | | 10/15/2019 | 49281-0650-70 | True | | 10/15/2019 | 126 | Novel influenza-H1N1-09, preservative-free | PMC |
| 49281-0650-90 | INFLUENZA A (H1N1) 2009 MONOVALENT VACCINE | Sanofi Pasteur Inc. | 9/15/2009 | 6/30/2010 | | 10/15/2019 | 49281-0650-90 | True | | 10/15/2019 | 126 | Novel influenza-H1N1-09, preservative-free | PMC |
| 49281-0703-55 | FLUZONE INTRADERMAL | Sanofi Pasteur Inc. | 7/1/2011 | 6/30/2012 | | 1/29/2018 | 49281-0703-55 | True | 00349281703553 | 2/27/2018 | 144 | influenza, seasonal, intradermal, preservative free | PMC |
| 49281-0705-55 | FLUZONE | Sanofi Pasteur Inc. | 7/2/2012 | 6/30/2013 | | 12/7/2017 | 49281-0705-55 | True | 00349281705557 | 7/5/2018 | 144 | influenza, seasonal, intradermal, preservative free | PMC |
| 49281-0707-55 | FLUZONE | Sanofi Pasteur Inc. | 6/28/2013 | 6/30/2014 | | 12/7/2017 | 49281-0707-48 | False | 00349281707483 | 2/22/2018 | 144 | influenza, seasonal, intradermal, preservative free | PMC |
| 49281-0708-40 | FLUZONE INTRADERMAL QUADRIVALENT | Sanofi Pasteur Inc. | 12/11/2014 | 6/30/2015 | | 12/7/2017 | 49281-0708-48 | False | | 7/5/2018 | 166 | influenza, intradermal, quadrivalent, preservative free | PMC |
| 49281-0709-55 | FLUZONE Intradermal | Sanofi Pasteur Inc. | 6/27/2014 | 6/30/2015 | | 7/12/2018 | 49281-0709-48 | False | 00349281709487 | 7/5/2018 | 144 | influenza, seasonal, intradermal, preservative free | PMC |
| 49281-0710-40 | FLUZONE INTRADERMAL QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2016 | 6/30/2017 | | 7/11/2018 | 49281-0710-48 | False | | 5/30/2018 | 166 | influenza, intradermal, quadrivalent, preservative free | PMC |
| 49281-0712-40 | FLUZONE INTRADERMAL QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2017 | 6/30/2018 | | 7/13/2018 | 49281-0712-48 | False | 00349281712487 | 7/9/2018 | 166 | influenza, intradermal, quadrivalent, preservative free | PMC |
| 49281-0718-10 | Flublok Quadrivalent | Sanofi Pasteur Inc. | 6/29/2018 | 6/30/2019 | | 7/16/2019 | 49281-0718-88 | False | 00349281718885 | 7/16/2019 | 185 | Influenza, recombinant, quadrivalent, PF | PMC |
| 49281-0719-10 | Flublok Quadrivalent | Sanofi Pasteur Inc. | 7/1/2019 | 6/30/2020 | | 7/18/2024 | 49281-0719-88 | False | 00349281719882 | 7/18/2024 | 185 | Influenza, recombinant, quadrivalent, PF | PMC |
| 49281-0720-10 | Flublok Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 7/1/2020 | 6/30/2021 | | 7/18/2024 | 49281-0720-88 | False | | 7/18/2024 | 185 | Influenza, recombinant, quadrivalent, PF | PMC |
| 49281-0721-10 | Flublok Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 7/2/2021 | 6/30/2022 | 00349281721106 | 7/18/2024 | 49281-0721-88 | False | 00349281721885 | 7/18/2024 | 185 | Influenza, recombinant, quadrivalent, PF | PMC |
| 49281-0722-10 | Flublok Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 7/1/2022 | 6/30/2023 | 00349281722103 | 8/6/2025 | 49281-0722-88 | False | 00349281722882 | 8/6/2025 | 185 | Influenza, recombinant, quadrivalent, PF | PMC |
| 49281-0723-10 | Flublok Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 6/30/2023 | 6/30/2024 | | 7/18/2024 | 49281-0723-88 | False | 00349281723889 | 9/19/2024 | 185 | Influenza, recombinant, quadrivalent, PF | PMC |
| 49281-0724-10 | FLUBLOK TRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/1/2024 | 6/30/2025 | 00349281724107 | 7/16/2025 | 49281-0724-88 | False | 00349281724886 | 7/16/2025 | 155 | Influenza, recombinant, trivalent, PF | PMC |
| 49281-0725-10 | FLUBLOK TRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/1/2025 | | | 7/25/2025 | 49281-0725-88 | False | | 7/25/2025 | 155 | Influenza, recombinant, trivalent, PF | PMC |
| 49281-0790-20 | Typhim Vi | Sanofi Vaccines US Inc. | 11/28/1994 | | 00349281790201 | 2/24/2026 | 49281-0790-38 | False | 00349281790386 | 2/24/2026 | 101 | typhoid, ViCPs | PMC |
| 49281-0790-51 | Typhim Vi | Sanofi Vaccines US Inc. | 11/28/1994 | | 00349281790515 | 2/24/2026 | 49281-0790-88 | False | 00349281790881 | 2/24/2026 | 101 | typhoid, ViCPs | PMC |
| 49281-0800-83 | TETANUS TOXOID ADSORBED | Sanofi Pasteur Inc. | 9/23/2005 | 5/5/2017 | | 5/30/2018 | 49281-0800-83 | True | | 5/30/2018 | 35 | tetanus toxoid, adsorbed | PMC |
| 49281-0820-10 | TETANUS TOXOID ADSORBED | Sanofi Pasteur Inc. | 9/23/2005 | 5/5/2017 | | 5/30/2018 | 49281-0820-10 | True | | 5/30/2018 | 35 | tetanus toxoid, adsorbed | PMC |
| 49281-0860-10 | IPOL | Sanofi Vaccines US Inc. | 12/21/1990 | | 00349281860102 | 6/9/2026 | 49281-0860-78 | False | 00349281860782 | 6/9/2026 | 10 | IPV | PMC |
| 49281-0860-10 | IPOL | Sanofi Vaccines US Inc. | 12/21/1990 | | 00349281860102 | 6/9/2026 | 49281-0860-88 | False | 00349281860881 | 6/8/2018 | 10 | IPV | PMC |
| 49281-0860-55 | IPOL | Sanofi Pasteur Inc. | 12/21/1990 | 6/16/2011 | 00349281860553 | 11/8/2021 | 49281-0860-78 | False | 00349281860782 | 6/9/2026 | 10 | IPV | PMC |
| 49281-0913-01 | STAMARIL | Sanofi Pasteur Inc. | 9/27/2016 | 10/31/2021 | 00349281913013 | 8/12/2025 | 49281-0913-01 | True | 00349281913013 | 8/12/2025 | 183 | Yellow fever vaccine live - alt | PMC |
| 49281-0915-01 | YF-VAX | Sanofi Vaccines US Inc. | 5/22/1953 | | 00349281915017 | 4/2/2026 | 49281-0915-58 | False | 00349281915581 | 4/2/2026 | 37 | yellow fever live | PMC |
| 49281-0915-05 | YF-VAX | Sanofi Vaccines US Inc. | 5/22/1953 | | 00349281915055 | 4/2/2026 | 49281-0915-68 | False | 00349281915680 | 4/2/2026 | 37 | yellow fever live | PMC |
| 49281-0933-50 | FLUZONE High-Dose Quadrivalent Southern Hemisphere | Sanofi Pasteur Inc. | 3/26/2024 | 12/31/2024 | | 1/27/2025 | 49281-0933-88 | False | | 1/24/2025 | 231 | influenza, Southern Hemisphere, high-dose, quadrivalent | PMC |
| 50090-1502-00 | HAVRIX | A-S Medication Solutions | 8/1/2021 | | | 3/13/2024 | 50090-1502-09 | False | | 2/3/2023 | 52 | Hep A, adult | SKB |
| 50090-1693-09 | IPOL | A-S Medication Solutions | 8/17/2018 | | | 2/8/2024 | 50090-1693-00 | False | | 2/2/2023 | 10 | IPV | PMC |
| 50090-1860-00 | M-M-R II | A-S Medication Solutions | 6/11/2025 | | | 6/26/2025 | 50090-1860-09 | False | | 6/11/2025 | 03 | MMR | MSD |
| 50090-2062-00 | TENIVAC | A-S Medication Solutions | 6/30/2023 | | | 7/11/2023 | 50090-2062-01 | False | | 7/11/2023 | 113 | Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed | PMC |
| 50090-2883-00 | INFANRIX | A-S Medication Solutions | 9/21/2018 | 1/1/2020 | | 1/10/2023 | 50090-2883-09 | False | | 1/13/2023 | 20 | DTaP | SKB |
| 50090-3096-00 | RabAvert | A-S Medication Solutions | 8/17/2018 | 1/1/2020 | | 1/10/2023 | 58160-0966-01 | False | | 3/13/2024 | 176 | Rabies - IM fibroblast culture | SKB |
| 50090-3469-00 | HEPLISAV-B | A-S Medication Solutions | 1/1/2018 | 1/1/2020 | | 1/21/2020 | 50090-3469-09 | False | | 4/29/2025 | 189 | HepB-CpG | DVX |
| 50090-3781-00 | HAVRIX | A-S Medication Solutions | 7/1/2024 | | | 7/12/2024 | 50090-3781-01 | False | | 7/12/2024 | 83 | Hep A, ped/adol, 2 dose | SKB |
| 50090-4526-00 | HEPLISAV-B | A-S Medication Solutions | 4/22/2025 | | | 4/30/2025 | 50090-4526-01 | False | | 4/29/2025 | 189 | HepB-CpG | DVX |
| 50090-4958-01 | GARDASIL 9 | A-S Medication Solutions | 5/22/2023 | | | 6/6/2023 | 50090-4958-00 | False | | 5/25/2023 | 165 | HPV9 | MSD |
| 50090-5147-00 | Shingrix | A-S Medication Solutions | 10/1/2020 | 1/6/2023 | | 1/13/2023 | 58160-0828-01 | False | 10358160828017 | 9/9/2025 | 187 | zoster recombinant | SKB |
| 50090-6026-00 | PREVNAR 20 | A-S Medication Solutions | 8/10/2021 | | | 3/1/2024 | 50090-6026-01 | False | | 3/1/2024 | 216 | Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF | PFR |
| 50090-6180-00 | MENQUADFI | A-S Medication Solutions | 5/3/2023 | | | 5/10/2023 | 50090-6180-01 | False | | 2/15/2024 | 203 | meningococcal conjugate quadrivalent, MenACWY-TT (MCV4) | PMC |
| 50090-7036-00 | PNEUMOVAX 23 | A-S Medication Solutions | 3/11/2024 | | | 3/12/2024 | 50090-7036-01 | False | | 3/12/2024 | 33 | pneumococcal polysaccharide PPV23 | MSD |
| 50090-7541-00 | PEDIARIX | A-S Medication Solutions | 8/20/2025 | | | 9/8/2025 | 50090-7541-01 | False | | 9/8/2025 | 110 | DTaP-Hep B-IPV | SKB |
| 50632-0001-02 | JYNNEOS | Bavarian Nordic A/S | 3/17/2021 | | 00350632001020 | 9/26/2024 | 50632-0001-01 | False | | 2/1/2023 | 206 | Vaccinia, smallpox monkeypox vaccine live, PF, SQ or ID injection | BN |
| 50632-0001-03 | JYNNEOS | Bavarian Nordic A/S | 3/17/2021 | | 00350632001037 | 9/26/2024 | 50632-0001-01 | False | | 2/1/2023 | 206 | Vaccinia, smallpox monkeypox vaccine live, PF, SQ or ID injection | BN |
| 50632-0002-02 | JYNNEOS | Bavarian Nordic A/S | 4/14/2025 | | | 4/30/2025 | 50632-0002-01 | False | | 4/30/2025 | 206 | Vaccinia, smallpox monkeypox vaccine live, PF, SQ or ID injection | BN |
| 50632-0010-01 | RabAvert | Bavarian Nordic A/S | 5/24/2021 | | | 2/21/2023 | 50632-0013-01 | False | | 2/21/2023 | 176 | Rabies - IM fibroblast culture | BN |
| 50632-0015-02 | Vaxchora | Bavarian Nordic A/S | 6/1/2024 | | 00350632015027 | 9/26/2024 | 50632-0015-02 | True | | 6/14/2024 | 174 | cholera, live attenuated | BN |
| 50632-0016-02 | Vivotif | Bavarian Nordic A/S | 7/1/2024 | | | 7/12/2024 | 50632-0016-04 | False | | 7/12/2024 | 25 | typhoid, oral | BN |
| 50632-0018-02 | VIMKUNYA | Bavarian Nordic A/S | 3/1/2025 | | | 3/18/2025 | 50632-0018-04 | False | | 3/18/2025 | 329 | Chikungunya, VLP, recombinant, 0.8 mL, PF | BN |
| 50632-0022-02 | JYNNEOS | Bavarian Nordic A/S | 2/14/2025 | | | 3/18/2025 | 50632-0022-04 | False | | 3/6/2025 | 206 | Vaccinia, smallpox monkeypox vaccine live, PF, SQ or ID injection | BN |
| 50632-0023-02 | JYNNEOS | Bavarian Nordic A/S | 2/14/2025 | | | 3/6/2025 | 50632-0023-04 | False | | 3/6/2025 | 206 | Vaccinia, smallpox monkeypox vaccine live, PF, SQ or ID injection | BN |
| 50632-0024-02 | JYNNEOS | Bavarian Nordic A/S | 12/31/2025 | | | 1/19/2026 | 50632-0024-04 | False | | 1/16/2026 | 206 | Vaccinia, smallpox monkeypox vaccine live, PF, SQ or ID injection | BN |
| 51285-0138-50 | Adenovirus Type 4 and Type 7 Vaccine, Live | Teva Women's Health, Inc. | 5/31/2011 | | | 7/12/2018 | 51285-0175-02 | False | | 1/27/2014 | 143 | Adenovirus types 4 and 7 | BRR |
| 51285-0138-50 | Adenovirus Type 4 and Type 7 Vaccine, Live | Teva Women's Health, Inc. | 5/31/2011 | | | 7/12/2018 | 51285-0175-02 | False | | 1/27/2014 | 143 | Adenovirus types 4 and 7 | TVA |
| 51285-0138-50 | Adenovirus Type 4 and Type 7 Vaccine, Live | Teva Women's Health, Inc. | 5/31/2011 | | | 7/12/2018 | 51285-0174-02 | False | | 1/27/2014 | 143 | Adenovirus types 4 and 7 | BRR |
| 51285-0138-50 | Adenovirus Type 4 and Type 7 Vaccine, Live | Teva Women's Health, Inc. | 5/31/2011 | | | 7/12/2018 | 51285-0174-02 | False | | 1/27/2014 | 143 | Adenovirus types 4 and 7 | TVA |
| 54868-0734-00 | ENGERIX-B | Physicians Total Care, Inc. | 8/5/2002 | 6/30/2012 | | 4/6/2018 | 54868-0734-00 | True | | 4/6/2018 | 43 | Hep B, adult | SKB |
| 54868-0980-00 | M-M-R II | Physicians Total Care, Inc. | 8/7/1996 | 6/30/2012 | | 1/29/2018 | 54868-0980-00 | True | | 1/29/2018 | 03 | MMR | MSD |
| 54868-2219-00 | RECOMBIVAX HB | Physicians Total Care, Inc. | 7/23/1986 | 6/30/2012 | | 7/13/2018 | 54868-2219-00 | True | | 4/6/2018 | 43 | Hep B, adult | MSD |
| 54868-2219-01 | RECOMBIVAX HB | Physicians Total Care, Inc. | 7/23/1986 | 6/30/2012 | | 7/13/2018 | 54868-2219-01 | True | | 4/6/2018 | 43 | Hep B, adult | MSD |
| 54868-3339-01 | PNEUMOVAX 23 | PHYSICIANS TOTAL CARE, INC | 9/20/1994 | 6/30/2009 | | 7/13/2018 | 54868-3339-09 | False | | 2/22/2018 | 33 | pneumococcal polysaccharide PPV23 | MSD |
| 54868-4320-00 | PNEUMOVAX 23 | PHYSICIANS TOTAL CARE, INC | 2/20/2006 | 6/30/2011 | | 7/13/2018 | 54868-4320-09 | False | | 1/27/2014 | 33 | pneumococcal polysaccharide PPV23 | MSD |
| 54868-6177-00 | FLUZONE | PHYSICIANS TOTAL CARE, INC | 9/16/2010 | 6/30/2011 | | 4/6/2018 | 54868-6177-00 | True | | 4/6/2018 | 141 | Influenza, split virus, trivalent, preservative | PMC |
| 54868-6180-00 | FLUZONE | PHYSICIANS TOTAL CARE, INC | 9/21/2010 | 6/30/2011 | | 4/6/2018 | 54868-6180-00 | True | | 4/6/2018 | 140 | Influenza, split virus, trivalent, PF | PMC |
| 55045-3841-01 | HAVRIX | Dispensing Solutions, Inc. | 4/13/2007 | 10/4/2019 | | 10/15/2019 | 55045-3841-01 | True | | 2/5/2021 | 52 | Hep A, adult | SKB |
| 58160-0726-15 | Hiberix | GlaxoSmithKline Biologicals SA | 12/20/2023 | | 00358160726156 | 1/28/2025 | 58160-0816-03 | False | | 1/28/2025 | 48 | Hib (PRP-T) | SKB |
| 58160-0740-21 | Rotarix | GlaxoSmithKline Biologicals SA | 2/1/2023 | | 00358160740213 | 4/24/2023 | 58160-0740-02 | False | 10358160740029 | 4/24/2023 | 119 | rotavirus, monovalent | SKB |
| 58160-0757-15 | PENMENVY | GlaxoSmithKline Biologicals SA | 2/14/2025 | | 20358160757154 | 11/13/2025 | 58160-0750-03 | False | | 3/18/2025 | 328 | Meningococcal oligosaccharide (MenACWY), (MenB), PF | SKB |
| 58160-0757-15 | PENMENVY | GlaxoSmithKline Biologicals SA | 2/14/2025 | | 20358160757154 | 11/13/2025 | 58160-0730-03 | False | | 3/18/2025 | 328 | Meningococcal oligosaccharide (MenACWY), (MenB), PF | SKB |
| 58160-0801-11 | Menhibrix | GlaxoSmithKline Biologicals SA | 9/3/2013 | 9/17/2017 | 00358160801112 | 5/30/2018 | 58160-0809-01 | False | 00358160809019 | 5/30/2018 | 148 | Meningococcal C/Y-HIB PRP | SKB |
| 58160-0806-05 | HIBERIX | GlaxoSmithKline Biologicals SA | 8/24/2009 | 12/15/2011 | | 6/8/2018 | 58160-0806-01 | False | 00358160806018 | 6/8/2018 | 48 | Hib (PRP-T) | SKB |
| 58160-0808-15 | Influenza A (H5N1) Monovalent Vaccine, Adjuvanted | GlaxoSmithKline | | 1/18/2018 | | 3/27/2023 | 58160-0802-02 | False | | 3/23/2023 | 160 | Influenza A monovalent (H5N1), ADJUVANTED-2013 | SKB |
| 58160-0808-15 | Influenza A (H5N1) Monovalent Vaccine, Adjuvanted | GlaxoSmithKline | | 1/18/2018 | | 3/27/2023 | 58160-0804-01 | False | | 3/27/2023 | 160 | Influenza A monovalent (H5N1), ADJUVANTED-2013 | SKB |
| 58160-0809-05 | MENHIBRIX | GlaxoSmithKline Biologicals SA | 9/3/2013 | 9/17/2017 | | 5/30/2018 | 58160-0809-01 | False | 00358160809019 | 5/30/2018 | 148 | Meningococcal C/Y-HIB PRP | SKB |
| 58160-0810-11 | INFANRIX | GlaxoSmithKline Biologicals SA | 7/24/2009 | 12/14/2022 | 00358160810114 | 12/16/2022 | 58160-0810-01 | False | 10358160810012 | 12/16/2022 | 20 | DTaP | SKB |
| 58160-0810-52 | INFANRIX | GlaxoSmithKline Biologicals SA | 7/24/2009 | | 00358160810527 | 1/31/2022 | 58160-0810-43 | False | 10358160810432 | 2/1/2023 | 20 | DTaP | SKB |
| 58160-0811-51 | PEDIARIX | GlaxoSmithKline Biologicals SA | 7/24/2009 | 2/24/2011 | | 6/8/2018 | 58160-0811-41 | False | | 6/8/2018 | 110 | DTaP-Hep B-IPV | SKB |
| 58160-0811-52 | PEDIARIX | GlaxoSmithKline Biologicals SA | 7/24/2009 | | 00358160811524 | 1/31/2022 | 58160-0811-43 | False | 10358160811439 | 2/1/2023 | 110 | DTaP-Hep B-IPV | SKB |
| 58160-0812-11 | KINRIX | GlaxoSmithKline Biologicals SA | 7/9/2008 | 6/10/2022 | 00358160812118 | 6/15/2022 | 58160-0812-01 | False | 10358160812016 | 6/14/2022 | 130 | DTaP-IPV | SKB |
| 58160-0812-52 | KINRIX | GlaxoSmithKline Biologicals SA | 7/9/2008 | | 00358160812521 | 1/31/2022 | 58160-0812-43 | False | 10358160812436 | 2/1/2023 | 130 | DTaP-IPV | SKB |
| 58160-0815-11 | TWINRIX | GlaxoSmithKline Biologicals SA | 6/7/2007 | 1/18/2018 | 00358160815119 | 5/30/2018 | 58160-0815-01 | False | 00358160815010 | 6/8/2018 | 104 | Hep A-Hep B | SKB |
| 58160-0815-34 | TWINRIX | GlaxoSmithKline Biologicals SA | 6/7/2007 | 1/18/2018 | 00358160815348 | 5/30/2018 | 58160-0815-05 | False | 00358160815058 | 5/30/2018 | 104 | Hep A-Hep B | SKB |
| 58160-0815-46 | TWINRIX | GlaxoSmithKline Biologicals SA | 6/7/2007 | 2/3/2011 | | 6/8/2018 | 58160-0815-41 | False | | 3/23/2023 | 104 | Hep A-Hep B | SKB |
| 58160-0815-48 | TWINRIX | GlaxoSmithKline Biologicals SA | 6/7/2007 | 4/27/2011 | | 6/8/2018 | 58160-0815-43 | False | 10358160815437 | 2/13/2024 | 104 | Hep A-Hep B | SKB |
| 58160-0815-52 | TWINRIX | GlaxoSmithKline Biologicals SA | 6/7/2007 | | 00358160815522 | 2/13/2024 | 58160-0815-43 | False | 10358160815437 | 2/13/2024 | 104 | Hep A-Hep B | SKB |
| 58160-0816-05 | Hiberix | GlaxoSmithKline Biologicals SA | 12/21/2015 | | 00358160816055 | 1/28/2025 | 58160-0816-01 | False | 10358160816014 | 1/28/2025 | 48 | Hib (PRP-T) | SKB |
| 58160-0818-11 | Hiberix | GlaxoSmithKline Biologicals SA | 12/21/2015 | | 00358160818110 | 1/28/2025 | 58160-0816-05 | False | 10358160816052 | 1/28/2025 | 48 | Hib (PRP-T) | SKB |
| 58160-0819-12 | Shingrix | GlaxoSmithKline Biologicals SA | 10/20/2017 | 8/23/2025 | 00358160819124 | 9/9/2025 | 58160-0828-01 | False | 10358160828017 | 9/9/2025 | 187 | zoster recombinant | SKB |
| 58160-0820-11 | ENGERIX-B | GlaxoSmithKline Biologicals SA | 4/25/2007 | 8/30/2019 | 00358160820113 | 9/4/2019 | 58160-0820-01 | False | 10358160820011 | 9/4/2019 | 08 | Hep B, adolescent or pediatric | SKB |
| 58160-0820-52 | ENGERIX-B | GlaxoSmithKline Biologicals SA | 4/25/2007 | | 00358160820526 | 12/7/2017 | 58160-0820-43 | False | 10358160820431 | 2/1/2023 | 08 | Hep B, adolescent or pediatric | SKB |
| 58160-0821-11 | ENGERIX-B | GlaxoSmithKline Biologicals SA | 3/28/2007 | | 00358160821110 | 12/7/2017 | 58160-0821-01 | False | 10358160821018 | 2/1/2023 | 44 | Hep B, high-dosage, dialysis or IC | SKB |
| 58160-0821-11 | ENGERIX-B | GlaxoSmithKline Biologicals SA | 3/28/2007 | | 00358160821110 | 12/7/2017 | 58160-0821-01 | False | 10358160821018 | 2/1/2023 | 43 | Hep B, adult | SKB |
| 58160-0821-34 | ENGERIX-B | GlaxoSmithKline Biologicals SA | 3/28/2007 | 2/18/2025 | 00358160821349 | 3/11/2025 | 58160-0821-05 | False | 10358160821056 | 2/18/2025 | 44 | Hep B, high-dosage, dialysis or IC | SKB |
| 58160-0821-34 | ENGERIX-B | GlaxoSmithKline Biologicals SA | 3/28/2007 | 2/18/2025 | 00358160821349 | 3/11/2025 | 58160-0821-05 | False | 10358160821056 | 2/18/2025 | 43 | Hep B, adult | SKB |
| 58160-0821-52 | ENGERIX-B | GlaxoSmithKline Biologicals SA | 3/28/2007 | | 00358160821523 | 12/7/2017 | 58160-0821-43 | False | 10358160821438 | 2/1/2023 | 44 | Hep B, high-dosage, dialysis or IC | SKB |
| 58160-0821-52 | ENGERIX-B | GlaxoSmithKline Biologicals SA | 3/28/2007 | | 00358160821523 | 12/7/2017 | 58160-0821-43 | False | 10358160821438 | 2/1/2023 | 43 | Hep B, adult | SKB |
| 58160-0823-11 | Shingrix | GlaxoSmithKline Biologicals SA | 10/20/2017 | | 00358160823114 | 10/8/2019 | 58160-0828-03 | False | 10358160828031 | 2/21/2023 | 187 | zoster recombinant | SKB |
| 58160-0824-15 | Priorix | GlaxoSmithKline Biologicals SA | 6/3/2022 | | 00358160824159 | 10/17/2022 | 58160-0831-03 | False | 10358160831031 | 10/17/2022 | 03 | MMR | SKB |
| 58160-0825-11 | HAVRIX | GlaxoSmithKline Biologicals SA | 2/16/2007 | 2/11/2021 | 00358160825118 | 4/5/2021 | 58160-0825-01 | False | 10358160825016 | 3/23/2021 | 83 | Hep A, ped/adol, 2 dose | SKB |
| 58160-0825-52 | HAVRIX | GlaxoSmithKline Biologicals SA | 2/16/2007 | | 00358160825521 | 12/7/2017 | 58160-0825-43 | False | 10358160825436 | 2/1/2023 | 83 | Hep A, ped/adol, 2 dose | SKB |
| 58160-0826-11 | HAVRIX | GlaxoSmithKline Biologicals SA | 4/13/2007 | 2/11/2021 | 00358160826115 | 4/5/2021 | 58160-0826-01 | False | 10358160826013 | 3/23/2021 | 52 | Hep A, adult | SKB |
| 58160-0826-34 | HAVRIX | GlaxoSmithKline Biologicals SA | 4/13/2007 | 3/3/2020 | 00358160826344 | 3/11/2020 | 58160-0826-05 | False | 10358160826051 | 3/11/2020 | 52 | Hep A, adult | SKB |
| 58160-0826-52 | HAVRIX | GlaxoSmithKline Biologicals SA | 4/13/2007 | | 00358160826528 | 12/7/2017 | 58160-0826-43 | False | 10358160826433 | 2/1/2023 | 52 | Hep A, adult | SKB |
| 58160-0827-30 | Menveo | GlaxoSmithKline Biologicals SA | 12/9/2022 | | 00358160827303 | 4/24/2023 | 58160-0827-03 | False | 10358160827034 | 5/12/2023 | 136 | Meningococcal MCV4O | SKB |
| 58160-0830-34 | CERVARIX | GlaxoSmithKline Biologicals SA | 10/16/2009 | 11/29/2016 | 00358160830341 | 5/30/2018 | 58160-0830-05 | False | | 5/30/2018 | 118 | HPV, bivalent | SKB |
| 58160-0830-52 | CERVARIX | GlaxoSmithKline Biologicals SA | 10/16/2009 | 11/29/2016 | 00358160830525 | 5/30/2018 | 58160-0830-43 | False | 00358160830433 | 5/30/2018 | 118 | HPV, bivalent | SKB |
| 58160-0842-11 | BOOSTRIX | GlaxoSmithKline Biologicals SA | 7/24/2009 | | 00358160842115 | 1/31/2022 | 58160-0842-01 | False | 10358160842013 | 2/1/2023 | 115 | Tdap | SKB |
| 58160-0842-34 | BOOSTRIX | GlaxoSmithKline Biologicals SA | 7/24/2009 | 10/26/2020 | 00358160842344 | 1/12/2021 | 58160-0842-05 | False | 10358160842051 | 1/19/2023 | 115 | Tdap | SKB |
| 58160-0842-51 | BOOSTRIX | GlaxoSmithKline Biologicals SA | 7/24/2009 | 6/15/2011 | 00358160842511 | 6/8/2018 | 58160-0842-41 | False | | 6/8/2018 | 115 | Tdap | SKB |
| 58160-0842-52 | BOOSTRIX | GlaxoSmithKline Biologicals SA | 7/24/2009 | | 00358160842528 | 1/31/2022 | 58160-0842-43 | False | 10358160842433 | 2/1/2023 | 115 | Tdap | SKB |
| 58160-0848-11 | Arexvy | GlaxoSmithKline Biologicals SA | 5/3/2023 | | 00358160848117 | 6/4/2024 | 58160-0723-03 | False | 10358160723039 | 6/4/2024 | 303 | RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF | SKB |
| 58160-0849-52 | Shingrix | GlaxoSmithKline Biologicals SA | 7/16/2025 | | | 7/30/2025 | 58160-0849-43 | False | | 7/30/2025 | 187 | zoster recombinant | SKB |
| 58160-0854-52 | ROTARIX | GlaxoSmithKline Biologicals SA | 1/13/2011 | 2/24/2025 | 00358160854521 | 3/11/2025 | 58160-0851-01 | False | 10358160851015 | 3/11/2025 | 119 | rotavirus, monovalent | SKB |
| 58160-0879-52 | FLUARIX | GlaxoSmithKline Biologicals SA | 7/20/2012 | 6/30/2013 | | 12/7/2017 | 58160-0879-41 | False | | 11/20/2017 | 140 | Influenza, split virus, trivalent, PF | SKB |
| 58160-0880-52 | FLUARIX | GlaxoSmithKline Biologicals SA | 7/1/2013 | 6/30/2014 | | 12/7/2017 | 58160-0880-41 | False | | 11/20/2017 | 140 | Influenza, split virus, trivalent, PF | SKB |
| 58160-0881-52 | FLUARIX | GlaxoSmithKline Biologicals SA | 6/27/2014 | 6/30/2015 | 00358160881527 | 5/30/2018 | 58160-0881-41 | False | 00358160881411 | 5/30/2018 | 140 | Influenza, split virus, trivalent, PF | SKB |
| 58160-0882-12 | Arexvy | GlaxoSmithKline Biologicals SA | 4/30/2026 | | | 6/3/2026 | 58160-0719-03 | False | | 6/10/2026 | 303 | RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF | SKB |
| 58160-0883-52 | FLUARIX | GlaxoSmithKline Biologicals SA | 8/3/2015 | 8/4/2015 | | 5/30/2018 | 58160-0883-41 | False | 00358160883415 | 5/30/2018 | 140 | Influenza, split virus, trivalent, PF | SKB |
| 58160-0884-52 | FLUARIX | GlaxoSmithKline Biologicals SA | 7/1/2024 | 6/30/2025 | | 7/16/2025 | 58160-0884-41 | False | | 7/16/2025 | 140 | Influenza, split virus, trivalent, PF | SKB |
| 58160-0885-52 | FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 7/2/2020 | 6/30/2021 | | 7/18/2024 | 58160-0885-41 | False | | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | SKB |
| 58160-0887-52 | FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 7/2/2021 | 6/30/2022 | 00358160887529 | 7/18/2024 | 58160-0887-41 | False | 10358160887410 | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | SKB |
| 58160-0890-52 | FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 7/1/2022 | 6/30/2023 | 00358160890529 | 7/18/2024 | 58160-0890-41 | False | 10358160890410 | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | SKB |
| 58160-0894-15 | Arexvy | GlaxoSmithKline Biologicals SA | 4/30/2026 | | | 6/3/2026 | 58160-0719-03 | False | | 6/10/2026 | 303 | RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF | SKB |
| 58160-0896-52 | FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 7/2/2019 | 6/30/2020 | | 7/18/2024 | 58160-0896-41 | False | | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | SKB |
| 58160-0898-52 | FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 6/29/2018 | 6/30/2019 | 00358160898525 | 7/16/2019 | 58160-0898-41 | False | 10358160898416 | 7/16/2019 | 150 | Influenza, split virus, quadrivalent, PF | SKB |
| 58160-0900-52 | FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 7/1/2013 | 6/30/2014 | | 12/7/2017 | 58160-0900-41 | False | | 11/20/2017 | 150 | Influenza, split virus, quadrivalent, PF | SKB |
| 58160-0901-52 | FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 7/1/2014 | 6/30/2015 | 00358160901522 | 5/30/2018 | 58160-0901-41 | False | 00358160901416 | 5/30/2018 | 150 | Influenza, split virus, quadrivalent, PF | SKB |
| 58160-0903-52 | FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 7/1/2015 | 6/30/2016 | | 5/30/2018 | 58160-0903-41 | False | 00358160903410 | 5/30/2018 | 150 | Influenza, split virus, quadrivalent, PF | SKB |
| 58160-0905-52 | FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 7/1/2016 | 6/30/2017 | | 7/11/2018 | 58160-0905-41 | False | | 7/5/2018 | 150 | Influenza, split virus, quadrivalent, PF | SKB |
| 58160-0907-52 | FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 7/7/2017 | 6/30/2018 | | 7/9/2018 | 58160-0907-41 | False | | 7/9/2018 | 150 | Influenza, split virus, quadrivalent, PF | SKB |
| 58160-0909-52 | FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 6/30/2023 | 6/30/2024 | | 7/18/2024 | 58160-0909-41 | False | | 7/23/2024 | 150 | Influenza, split virus, quadrivalent, PF | SKB |
| 58160-0912-52 | FLUARIX | GlaxoSmithKline Biologicals SA | 7/1/2025 | | | 8/10/2025 | 58160-0912-41 | False | | 8/7/2025 | 140 | Influenza, split virus, trivalent, PF | SKB |
| 58160-0955-09 | Menveo | GlaxoSmithKline Biologicals SA | 3/1/2017 | | 00358160955099 | 12/16/2022 | 58160-0958-01 | False | 10358160958011 | 12/16/2022 | 136 | Meningococcal MCV4O | SKB |
| 58160-0955-09 | Menveo | GlaxoSmithKline Biologicals SA | 3/1/2017 | | 00358160955099 | 12/16/2022 | 58160-0959-01 | False | 10358160959018 | 12/16/2022 | 136 | Meningococcal MCV4O | SKB |
| 58160-0964-12 | RabAvert | GlaxoSmithKline Biologicals SA | 12/19/2016 | 1/31/2024 | 00358160964121 | 3/13/2024 | 58160-0966-01 | False | | 3/13/2024 | 176 | Rabies - IM fibroblast culture | SKB |
| 58160-0964-12 | RabAvert | GlaxoSmithKline Biologicals SA | 12/19/2016 | 1/31/2024 | 00358160964121 | 3/13/2024 | 58160-0966-12 | False | | 7/13/2018 | 176 | Rabies - IM fibroblast culture | SKB |
| 58160-0976-06 | Bexsero | GlaxoSmithKline Biologicals SA | 12/1/2016 | 12/31/2021 | 00358160976063 | 1/10/2022 | 58160-0976-02 | False | 10358160976022 | 2/1/2023 | 163 | meningococcal B, OMV | SKB |
| 58160-0976-20 | Bexsero | GlaxoSmithKline Biologicals SA | 12/1/2016 | | 00358160976209 | 1/31/2022 | 58160-0976-02 | False | 10358160976022 | 2/1/2023 | 163 | meningococcal B, OMV | SKB |
| 59267-0078-04 | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 6/17/2022 | 4/18/2023 | | 5/3/2023 | 59267-0078-01 | False | | 1/17/2024 | 219 | COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose | PFR |
| 59267-0304-02 | Pfizer-BioNTech Covid-19 Vaccine, Bivalent | Pfizer Manufacturing Belgium NV | 9/1/2022 | 9/11/2023 | | 10/26/2023 | 59267-0304-01 | False | | 10/26/2023 | 300 | COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose | PFR |
| 59267-0565-02 | Pfizer-BioNTech Covid-19 Vaccine, Bivalent | Pfizer Manufacturing Belgium NV | 10/12/2022 | 9/11/2023 | | 10/26/2023 | 59267-0565-01 | False | | 10/26/2023 | 301 | COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose | PFR |
| 59267-0609-02 | Pfizer-BioNTech Covid-19 Vaccine, Bivalent | Pfizer Manufacturing Belgium NV | 12/9/2022 | 9/11/2023 | | 10/26/2023 | 59267-0609-01 | False | | 10/26/2023 | 302 | COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose | PFR |
| 59267-1000-02 | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 12/12/2020 | 4/18/2023 | | 5/3/2023 | 59267-1000-01 | False | | 5/3/2023 | 208 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose | PFR |
| 59267-1000-03 | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 12/12/2020 | 4/18/2023 | | 5/3/2023 | 59267-1000-01 | False | | 5/3/2023 | 208 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose | PFR |
| 59267-1025-02 | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 10/1/2021 | 11/1/2021 | | 11/9/2021 | 59267-1025-01 | False | | 5/3/2023 | 217 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose | PFR |
| 59267-1025-03 | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 10/1/2021 | 4/18/2023 | | 5/3/2023 | 59267-1025-01 | False | | 5/3/2023 | 217 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose | PFR |
| 59267-1025-04 | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 10/1/2021 | 4/18/2023 | | 5/3/2023 | 59267-1025-01 | False | | 5/3/2023 | 217 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose | PFR |
| 59267-1055-02 | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 10/1/2021 | 11/1/2021 | | 11/9/2021 | 59267-1055-01 | False | | 5/3/2023 | 218 | COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose | PFR |
| 59267-1055-04 | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 10/1/2021 | 4/18/2023 | | 5/3/2023 | 59267-1055-01 | False | | 5/3/2023 | 218 | COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose | PFR |
| 59267-1404-02 | Pfizer-BioNTech Covid-19 Vaccine, Bivalent | Pfizer Manufacturing Belgium NV | 9/1/2022 | 9/11/2023 | | 10/26/2023 | 59267-1404-01 | False | | 10/26/2023 | 300 | COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose | PFR |
| 59267-4315-02 | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 9/11/2023 | 7/31/2024 | 00359267431523 | 9/19/2024 | 59267-4315-01 | False | 10359267431513 | 9/19/2024 | 308 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL | PFR |
| 59267-4331-02 | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 9/11/2023 | 8/31/2024 | 00359267433121 | 9/19/2024 | 59267-4331-01 | False | 10359267433111 | 9/19/2024 | 310 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL | PFR |
| 59267-4426-02 | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 8/22/2024 | 8/27/2025 | 00359267442628 | 9/9/2025 | 59267-4426-01 | False | 10359267442618 | 9/9/2025 | 308 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL | PFR |
| 59267-4438-02 | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 8/22/2024 | 8/27/2025 | 00359267443823 | 9/9/2025 | 59267-4438-01 | False | 10359267443813 | 9/9/2025 | 310 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL | PFR |
| 59676-0580-15 | Janssen COVID-19 Vaccine | Janssen Products, LP | 2/1/2021 | 6/20/2023 | | 7/11/2023 | 59676-0580-05 | False | | 7/10/2023 | 212 | COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL | JSN |
| 62195-0051-01 | Ixiaro | Vetter Pharma Fertigung GmbH & Co. KG | 11/23/2020 | | | 12/29/2020 | 62195-0051-01 | True | | 6/15/2018 | 134 | Japanese Encephalitis IM | VAL |
| 62195-0051-10 | Ixiaro | Vetter Pharma Fertigung GmbH & Co. KG | 3/30/2009 | 11/23/2020 | | 12/29/2020 | 62195-0051-01 | False | | 6/15/2018 | 134 | Japanese Encephalitis IM | VAL |
| 62577-0613-01 | Flucelvax | Novartis Vaccines and Diagnostics, Inc. | 7/1/2014 | 6/30/2015 | | 5/30/2018 | 62577-0613-11 | False | | 5/30/2018 | 153 | Influenza, MDCK, trivalent, PF | NOV |
| 62577-0614-01 | Flucelvax | Novartis Vaccines and Diagnostics, Inc. | 7/1/2014 | 6/30/2016 | | 7/6/2018 | 62577-0614-11 | False | | 7/5/2018 | 153 | Influenza, MDCK, trivalent, PF | NOV |
| 63361-0243-10 | VAXELIS | MSP Vaccine Company | 4/10/2020 | 5/12/2026 | 00363361243104 | 5/13/2026 | 63361-0243-58 | False | 00363361243586 | 5/13/2026 | 146 | DTaP,IPV,Hib,HepB | MSP |
| 63361-0243-15 | VAXELIS | MSP Vaccine Company | 10/1/2020 | | 00363361243159 | 9/19/2024 | 63361-0243-88 | False | 00363361243883 | 9/19/2024 | 146 | DTaP,IPV,Hib,HepB | MSP |
| 63361-0245-10 | VAXELIS | MCM Vaccine Co. | 12/21/2018 | 4/10/2020 | | 4/21/2020 | 63361-0245-58 | False | | 9/19/2024 | 146 | DTaP,IPV,Hib,HepB | PMC |
| 63851-0501-01 | RabAvert | Novartis Vaccines and Diagnostics GmbH | 10/20/1997 | 1/19/2017 | | 6/8/2018 | 63851-0511-11 | False | 00363851511119 | 4/15/2020 | 176 | Rabies - IM fibroblast culture | NOV |
| 63851-0501-02 | RabAvert | GSK Vaccines GmbH | 7/8/2014 | 3/31/2020 | 00363851501028 | 4/16/2020 | 63851-0511-11 | False | 00363851511119 | 4/15/2020 | 176 | Rabies - IM fibroblast culture | NOV |
| 63851-0612-01 | Flucelvax | Novartis Vaccines and Diagnostics GmbH | 8/30/2013 | 6/30/2014 | | 5/30/2018 | 63851-0612-11 | False | | 5/30/2018 | 153 | Influenza, MDCK, trivalent, PF | NOV |
| 63851-0613-01 | FLUCELVAX | Novartis Vaccines and Diagnostics GmbH | 7/1/2014 | 6/30/2015 | | 5/30/2018 | 63851-0613-11 | False | | 5/30/2018 | 153 | Influenza, MDCK, trivalent, PF | NOV |
| 64678-0211-01 | BioThrax | Emergent BioDefense Operations Lansing, LLC | 11/4/1970 | | | 6/10/2025 | 64678-0211-05 | False | | 6/10/2025 | 24 | Anthrax, pre-exposure prophylaxis, post-exposure prophylaxis | MIP |
| 66019-0107-01 | FLUMIST | MedImmune, LLC | 7/17/2009 | 4/19/2010 | | 7/13/2018 | 66019-0107-01 | True | | 2/13/2018 | 111 | Influenza, live, trivalent, intranasal, PF | MED |
| 66019-0108-10 | FLUMIST | MedImmune, LLC | 7/22/2010 | 6/30/2011 | | 7/13/2018 | 66019-0108-01 | False | | 1/29/2018 | 111 | Influenza, live, trivalent, intranasal, PF | MED |
| 66019-0109-10 | FLUMIST | MedImmune, LLC | 6/30/2011 | 7/19/2012 | | 7/13/2018 | 66019-0109-01 | False | | 1/29/2018 | 111 | Influenza, live, trivalent, intranasal, PF | MED |
| 66019-0110-10 | FluMist | MedImmune, LLC | 8/1/2012 | 7/18/2013 | | 7/13/2018 | 66019-0110-01 | False | | 11/20/2017 | 111 | Influenza, live, trivalent, intranasal, PF | MED |
| 66019-0112-10 | FluMist | MedImmune, LLC | 8/1/2025 | | | 8/7/2025 | 66019-0112-00 | False | | 8/7/2025 | 111 | Influenza, live, trivalent, intranasal, PF | MED |
| 66019-0112-51 | FluMist | MedImmune, LLC | 8/1/2025 | | | 8/7/2025 | 66019-0112-51 | True | | 8/7/2025 | 333 | Influenza, live, trivalent, intranasal, self/caregiver admin, PF | MED |
| 66019-0200-10 | Influenza A H1N1 Intranasal | MedImmune, LLC | 10/1/2009 | 4/13/2010 | | 7/13/2018 | 66019-0200-01 | False | | 1/29/2018 | 125 | Novel Influenza-H1N1-09, nasal | MED |
| 66019-0300-10 | FluMist Quadrivalent | MedImmune, LLC | 7/15/2013 | 6/30/2014 | | 7/13/2018 | 66019-0300-01 | False | | 5/30/2018 | 149 | Influenza, live, quadrivalent, intranasal | MED |
| 66019-0301-10 | FluMist Quadrivalent | MedImmune, LLC | 7/1/2014 | 6/30/2015 | | 7/12/2018 | 66019-0301-01 | False | | 5/30/2018 | 149 | Influenza, live, quadrivalent, intranasal | MED |
| 66019-0302-10 | FluMist Quadrivalent | MedImmune, LLC | 7/15/2013 | 6/30/2016 | | 7/13/2018 | 66019-0302-01 | False | | 5/30/2018 | 149 | Influenza, live, quadrivalent, intranasal | MED |
| 66019-0303-10 | FluMist Quadrivalent | MedImmune, LLC | 7/25/2016 | 6/30/2017 | | 7/12/2018 | 66019-0303-01 | False | | 5/30/2018 | 149 | Influenza, live, quadrivalent, intranasal | MED |
| 66019-0304-10 | FluMist Quadrivalent | MedImmune, LLC | 8/25/2017 | 6/30/2018 | | 8/20/2018 | 66019-0304-01 | False | | 8/20/2018 | 149 | Influenza, live, quadrivalent, intranasal | MED |
| 66019-0305-10 | FluMist Quadrivalent | MedImmune, LLC | 8/10/2018 | 4/30/2019 | | 5/21/2019 | 66019-0305-01 | False | | 5/21/2019 | 149 | Influenza, live, quadrivalent, intranasal | MED |
| 66019-0306-10 | FluMist Quadrivalent | MedImmune, LLC | 9/5/2019 | 3/6/2020 | | 7/18/2024 | 66019-0306-01 | False | | 7/18/2024 | 149 | Influenza, live, quadrivalent, intranasal | MED |
| 66019-0307-10 | FluMist Quadrivalent | MedImmune, LLC | 8/10/2020 | 4/1/2021 | | 7/18/2024 | 66019-0307-01 | False | | 7/18/2024 | 149 | Influenza, live, quadrivalent, intranasal | MED |
| 66019-0308-10 | FluMist Quadrivalent | MedImmune, LLC | 8/2/2021 | 3/15/2022 | 00366019308101 | 7/18/2024 | 66019-0308-01 | False | | 7/18/2024 | 149 | Influenza, live, quadrivalent, intranasal | MED |
| 66019-0309-10 | FluMist Quadrivalent | MedImmune, LLC | 8/8/2022 | 3/15/2023 | | 7/18/2024 | 66019-0309-01 | False | | 7/18/2024 | 149 | Influenza, live, quadrivalent, intranasal | MED |
| 66019-0310-10 | FluMist Quadrivalent | MedImmune, LLC | 8/14/2023 | 8/5/2024 | | 9/17/2024 | 66019-0310-01 | False | | 9/17/2024 | 149 | Influenza, live, quadrivalent, intranasal | MED |
| 66019-0311-10 | FluMist | MedImmune, LLC | 8/6/2024 | 6/30/2025 | | 7/28/2025 | 66019-0311-00 | False | | 7/24/2025 | 111 | Influenza, live, trivalent, intranasal, PF | MED |
| 66521-0000-01 | FLUAD | Novartis Vaccines and Diagnostics Limited | 11/24/2015 | 6/30/2016 | | 8/13/2018 | 66521-0000-11 | False | | 7/9/2018 | 168 | Influenza, adjuvanted, trivalent, PF | NOV |
| 66521-0112-02 | Fluvirin | Novartis Vaccines and Diagnostics Ltd | 8/12/1998 | 6/30/2010 | | 5/30/2018 | 66521-0112-02 | True | | 7/5/2018 | 140 | Influenza, split virus, trivalent, PF | NOV |
| 66521-0112-10 | Fluvirin | Novartis Vaccines and Diagnostics Ltd | 8/12/1998 | 6/30/2010 | | 5/30/2018 | 66521-0112-10 | True | | 7/5/2018 | 141 | Influenza, split virus, trivalent, preservative | NOV |
| 66521-0113-02 | FLUVIRIN | Novartis Vaccines and Diagnostics Limited | 8/12/1988 | 6/30/2011 | | 5/30/2018 | 66521-0113-02 | True | | 7/5/2018 | 140 | Influenza, split virus, trivalent, PF | NOV |
| 66521-0113-10 | FLUVIRIN | Novartis Vaccines and Diagnostics Limited | 8/12/1988 | 6/30/2011 | | 5/30/2018 | 66521-0113-10 | True | | 7/5/2018 | 141 | Influenza, split virus, trivalent, preservative | NOV |
| 66521-0114-02 | FLUVIRIN | Novartis Vaccines and Diagnostics Limited | 7/1/2011 | 6/30/2012 | | 5/30/2018 | 66521-0114-02 | True | | 4/23/2020 | 140 | Influenza, split virus, trivalent, PF | NOV |
| 66521-0114-10 | FLUVIRIN | Novartis Vaccines and Diagnostics Limited | 7/1/2011 | 6/30/2012 | | 5/30/2018 | 66521-0114-10 | True | | 5/30/2018 | 141 | Influenza, split virus, trivalent, preservative | NOV |
| 66521-0115-02 | FLUVIRIN | Novartis Vaccines and Diagnostics Limited | 7/20/2012 | 6/30/2013 | | 5/30/2018 | 66521-0115-02 | True | 00366521115020 | 7/5/2018 | 140 | Influenza, split virus, trivalent, PF | NOV |
| 66521-0115-10 | FLUVIRIN | Novartis Vaccines and Diagnostics Limited | 7/20/2012 | 6/30/2013 | | 5/30/2018 | 66521-0115-10 | True | | 7/5/2018 | 141 | Influenza, split virus, trivalent, preservative | NOV |
| 66521-0116-02 | Fluvirin | Novartis Vaccines and Diagnostics Limited | 7/30/2013 | 6/30/2014 | | 3/5/2018 | 66521-0116-12 | False | | 11/20/2017 | 140 | Influenza, split virus, trivalent, PF | NOV |
| 66521-0116-10 | Fluvirin | Novartis Vaccines and Diagnostics Limited | 7/30/2013 | 6/30/2014 | | 12/7/2017 | 66521-0116-11 | False | | 11/20/2017 | 141 | Influenza, split virus, trivalent, preservative | NOV |
| 66521-0117-02 | Fluvirin | Novartis Vaccines and Diagnostics Ltd | 7/1/2014 | 6/30/2015 | | 7/6/2018 | 66521-0117-12 | False | | 7/5/2018 | 140 | Influenza, split virus, trivalent, PF | NOV |
| 66521-0117-10 | Fluvirin | Novartis Vaccines and Diagnostics Ltd | 7/1/2014 | 6/30/2015 | | 7/6/2018 | 66521-0117-11 | False | 00366521117116 | 7/5/2018 | 141 | Influenza, split virus, trivalent, preservative | NOV |
| 66521-0118-02 | Fluvirin | Novartis Vaccines and Diagnostics Limited | 7/1/2015 | 6/30/2016 | | 7/11/2018 | 66521-0118-12 | False | | 7/9/2018 | 140 | Influenza, split virus, trivalent, PF | NOV |
| 66521-0118-10 | Fluvirin | Novartis Vaccines and Diagnostics Limited | 7/1/2015 | 6/30/2016 | | 7/11/2018 | 66521-0118-11 | False | | 7/9/2018 | 141 | Influenza, split virus, trivalent, preservative | NOV |
| 66521-0200-02 | Influenza A (H1N1) 2009 Monovalent Vaccine | Novartis Vaccines and Diagnostics Ltd | 9/15/2009 | 6/30/2010 | | 10/15/2019 | 66521-0200-02 | True | | 10/15/2019 | 127 | Novel influenza-H1N1-09 | NOV |
| 66521-0200-10 | Influenza A (H1N1) 2009 Monovalent Vaccine | Novartis Vaccines and Diagnostics Ltd | 9/15/2009 | 6/30/2010 | | 10/15/2019 | 66521-0200-10 | True | | 10/15/2019 | 126 | Novel influenza-H1N1-09, preservative-free | NOV |
| 69401-0000-02 | Vivotif | Emergent Travel Health Inc. | 3/16/1992 | 7/23/2025 | 00369401000027 | 8/12/2025 | 69401-0000-01 | False | | 7/31/2025 | 25 | typhoid, oral | PAX |
| 70460-0001-01 | Vaxchora | Paxvax, Inc. | 10/3/2016 | 8/1/2021 | | 8/16/2021 | 70460-0002-02 | False | | 7/23/2025 | 174 | cholera, live attenuated | PAX |
| 70460-0004-01 | Vaxchora | Emergent Travel Health Inc. | 9/15/2019 | 7/23/2025 | 00370460004017 | 8/12/2025 | 70460-0002-02 | False | | 7/23/2025 | 174 | cholera, live attenuated | PAX |
| 70461-0001-01 | FLUAD | Seqirus, Inc. | 7/1/2016 | 6/30/2017 | | 7/12/2018 | 70461-0001-11 | False | | 7/5/2018 | 168 | Influenza, adjuvanted, trivalent, PF | SEQ |
| 70461-0002-01 | FLUAD | Seqirus Inc. | 7/1/2017 | 6/30/2018 | | 7/9/2018 | 70461-0002-11 | False | | 7/9/2018 | 168 | Influenza, adjuvanted, trivalent, PF | SEQ |
| 70461-0018-03 | FLUAD | Seqirus, Inc. | 7/13/2018 | 7/31/2019 | | 8/22/2019 | 70461-0018-04 | False | | 8/15/2019 | 168 | Influenza, adjuvanted, trivalent, PF | SEQ |
| 70461-0019-03 | FLUAD | Seqirus, Inc. | 8/1/2019 | 6/30/2020 | 00370461019034 | 7/18/2024 | 70461-0019-04 | False | 00370461019041 | 7/18/2024 | 168 | Influenza, adjuvanted, trivalent, PF | SEQ |
| 70461-0020-03 | FLUAD | Seqirus, Inc. | 7/1/2020 | 7/31/2021 | | 7/18/2024 | 70461-0020-04 | False | | 7/18/2024 | 168 | Influenza, adjuvanted, trivalent, PF | SEQ |
| 70461-0024-03 | FLUAD | Seqirus, Inc. | 7/1/2024 | 6/30/2025 | 00370461024038 | 7/16/2025 | 70461-0024-04 | False | 00370461024045 | 7/16/2025 | 168 | Influenza, adjuvanted, trivalent, PF | SEQ |
| 70461-0025-03 | FLUAD | Seqirus, Inc. | 7/1/2025 | | 00370461025035 | 11/13/2025 | 70461-0025-04 | False | 00370461025042 | 11/13/2025 | 168 | Influenza, adjuvanted, trivalent, PF | SEQ |
| 70461-0119-02 | Fluvirin | Seqirus, Inc. | 7/1/2016 | 6/30/2017 | | 7/12/2018 | 70461-0119-12 | False | | 5/30/2018 | 140 | Influenza, split virus, trivalent, PF | SEQ |
| 70461-0119-10 | Fluvirin | Seqirus, Inc. | 7/1/2016 | 6/30/2017 | | 7/12/2018 | 70461-0119-11 | False | | 5/30/2018 | 141 | Influenza, split virus, trivalent, preservative | SEQ |
| 70461-0120-02 | Fluvirin | Seqirus Inc. | 7/1/2017 | 6/30/2018 | | 7/9/2018 | 70461-0120-12 | False | | 7/9/2018 | 140 | Influenza, split virus, trivalent, PF | SEQ |
| 70461-0120-03 | FLUAD QUADRIVALENT | Seqirus, Inc. | 7/1/2020 | 6/30/2021 | | 7/18/2024 | 70461-0120-04 | False | | 7/18/2024 | 205 | Influenza, adjuvanted, quadrivalent, PF | SEQ |
| 70461-0120-10 | Fluvirin | Seqirus Inc. | 7/1/2017 | 6/30/2018 | | 7/9/2018 | 70461-0120-11 | False | | 7/9/2018 | 141 | Influenza, split virus, trivalent, preservative | SEQ |
| 70461-0121-03 | FLUAD QUADRIVALENT | Seqirus, Inc. | 7/1/2021 | 6/30/2022 | | 7/18/2024 | 70461-0121-04 | False | | 7/18/2024 | 205 | Influenza, adjuvanted, quadrivalent, PF | SEQ |
| 70461-0122-03 | FLUAD QUADRIVALENT | Seqirus, Inc. | 7/1/2022 | 7/31/2023 | 00370461122031 | 7/18/2024 | 70461-0122-04 | False | 00370461122048 | 7/18/2024 | 205 | Influenza, adjuvanted, quadrivalent, PF | SEQ |
| 70461-0123-03 | FLUAD QUADRIVALENT | Seqirus, Inc. | 7/1/2023 | 6/30/2024 | 00370461123038 | 8/6/2024 | 70461-0123-04 | False | 00370461123045 | 8/6/2024 | 205 | Influenza, adjuvanted, quadrivalent, PF | SEQ |
| 70461-0200-01 | FLUCELVAX QUADRIVALENT | Seqirus, Inc. | 7/1/2016 | 6/30/2017 | | 7/13/2018 | 70461-0200-11 | False | | 7/5/2018 | 171 | Influenza, MDCK, quadrivalent, PF | SEQ |
| 70461-0201-01 | FLUCELVAX QUADRIVALENT (PREFILLED SYRINGE) | Seqirus, Inc. | 7/1/2017 | 6/30/2018 | | 7/9/2018 | 70461-0201-11 | False | | 7/9/2018 | 171 | Influenza, MDCK, quadrivalent, PF | SEQ |
| 70461-0301-10 | FLUCELVAX QUADRIVALENT (MULTI-DOSE VIAL) | Seqirus, Inc. | 7/1/2017 | 6/30/2018 | | 7/9/2018 | 70461-0301-12 | False | | 7/9/2018 | 186 | Influenza, MDCK, quadrivalent, preservative | SEQ |
| 70461-0318-03 | FLUCELVAX QUADRIVALENT (PREFILLED SYRINGE) | Seqirus, Inc. | 7/1/2018 | 7/31/2019 | | 1/23/2020 | 70461-0318-04 | False | | 8/22/2019 | 171 | Influenza, MDCK, quadrivalent, PF | SEQ |
| 70461-0319-03 | FLUCELVAX QUADRIVALENT | Seqirus, Inc. | 7/30/2019 | 7/31/2020 | 00370461319035 | 7/18/2024 | 70461-0319-04 | False | 00370461319042 | 7/18/2024 | 171 | Influenza, MDCK, quadrivalent, PF | SEQ |
| 70461-0320-03 | FLUCELVAX QUADRIVALENT | Seqirus Inc. | 7/2/2020 | 7/1/2021 | | 7/18/2024 | 70461-0320-04 | False | | 7/18/2024 | 171 | Influenza, MDCK, quadrivalent, PF | SEQ |
| 70461-0321-03 | FLUCELVAX QUADRIVALENT | Seqirus Inc. | 7/1/2021 | 6/30/2022 | | 7/18/2024 | 70461-0321-04 | False | | 7/18/2024 | 171 | Influenza, MDCK, quadrivalent, PF | SEQ |
| 70461-0322-03 | Flucelvax Quadrivalent | Seqirus Inc. | 7/1/2022 | 6/30/2023 | 00370461322035 | 7/18/2024 | 70461-0322-04 | False | 00370461322042 | 7/18/2024 | 171 | Influenza, MDCK, quadrivalent, PF | SEQ |
| 70461-0323-03 | Flucelvax Quadrivalent | Seqirus Inc. | 7/1/2023 | 6/30/2024 | | 8/6/2024 | 70461-0323-04 | False | 00370461323049 | 8/6/2024 | 171 | Influenza, MDCK, quadrivalent, PF | SEQ |
| 70461-0418-10 | FLUCELVAX QUADRIVALENT (MULTI-DOSE VIAL) | Seqirus, Inc. | 7/1/2018 | 7/31/2019 | | 8/22/2019 | 70461-0418-11 | False | | 8/22/2019 | 186 | Influenza, MDCK, quadrivalent, preservative | SEQ |
| 70461-0419-10 | FLUCELVAX QUADRIVALENT | Seqirus, Inc. | 7/30/2019 | 7/31/2020 | 00370461419100 | 7/18/2024 | 70461-0419-11 | False | 00370461419117 | 7/18/2024 | 186 | Influenza, MDCK, quadrivalent, preservative | SEQ |
| 70461-0420-10 | FLUCELVAX QUADRIVALENT | Seqirus Inc. | 7/2/2020 | 7/1/2021 | | 7/18/2024 | 70461-0420-11 | False | | 7/18/2024 | 186 | Influenza, MDCK, quadrivalent, preservative | SEQ |
| 70461-0421-10 | FLUCELVAX QUADRIVALENT | Seqirus Inc. | 7/2/2021 | 6/30/2022 | | 7/18/2024 | 70461-0421-11 | False | | 7/18/2024 | 186 | Influenza, MDCK, quadrivalent, preservative | SEQ |
| 70461-0422-10 | Flucelvax Quadrivalent | Seqirus Inc. | 7/1/2022 | 6/30/2023 | 00370461422100 | 7/18/2024 | 70461-0422-11 | False | 00370461422117 | 7/18/2024 | 186 | Influenza, MDCK, quadrivalent, preservative | SEQ |
| 70461-0423-10 | Flucelvax Quadrivalent | Seqirus Inc. | 7/1/2023 | 6/30/2024 | 00370461423107 | 8/6/2024 | 70461-0423-11 | False | 00370461423114 | 8/6/2024 | 186 | Influenza, MDCK, quadrivalent, preservative | SEQ |
| 70461-0554-10 | Flucelvax | Seqirus Inc. | 7/1/2024 | 6/30/2025 | 00370461554108 | 7/16/2025 | 70461-0554-11 | False | 00370461554115 | 7/16/2025 | 320 | Influenza, MDCK, trivalent, preservative | SEQ |
| 70461-0555-10 | Flucelvax | Seqirus Inc. | 7/1/2025 | | 00370461555105 | 11/13/2025 | 70461-0555-11 | False | 00370461555112 | 11/13/2025 | 320 | Influenza, MDCK, trivalent, preservative | SEQ |
| 70461-0654-03 | Flucelvax | Seqirus Inc. | 7/1/2024 | 6/30/2025 | 00370461654037 | 7/16/2025 | 70461-0654-04 | False | 00370461654044 | 7/16/2025 | 153 | Influenza, MDCK, trivalent, PF | SEQ |
| 70461-0655-03 | Flucelvax | Seqirus Inc. | 7/1/2025 | | 00370461655034 | 11/13/2025 | 70461-0655-04 | False | 00370461655041 | 11/13/2025 | 153 | Influenza, MDCK, trivalent, PF | SEQ |
| 71665-0001-02 | CYFENDUS | Emergent Product Development Gaithersburg Inc. | 9/19/2023 | | | 6/11/2024 | 71665-0001-01 | False | | 1/25/2024 | 318 | Anthrax, post-exposure prophylaxis | MIP |
| 71665-0330-02 | ACAM2000 | Emergent Product Development Gaithersburg Inc. | 8/31/2007 | | | 4/29/2025 | 71665-0330-01 | False | | 4/29/2025 | 75 | Vaccinia (smallpox, monkeypox), live | MIP |
| 71665-0330-03 | ACAM2000 | Emergent Product Development Gaithersburg Inc. | 2/25/2025 | | | 4/29/2025 | 71665-0330-01 | False | | 4/29/2025 | 75 | Vaccinia (smallpox, monkeypox), live | MIP |
| 71665-0430-02 | ACAM2000 | Emergent Product Development Gaithersburg Inc. | 2/25/2025 | | | 4/29/2025 | 71665-0430-01 | False | | 4/29/2025 | 75 | Vaccinia (smallpox, monkeypox), live | MIP |
| 71665-0430-03 | ACAM2000 | Emergent Product Development Gaithersburg Inc. | 2/25/2025 | | | 4/29/2025 | 71665-0430-01 | False | | 4/29/2025 | 75 | Vaccinia (smallpox, monkeypox), live | MIP |
| 75052-0001-10 | PREHEVBRIO | VBI Vaccines (Delaware) Inc. | 12/1/2021 | 11/15/2024 | | 8/6/2025 | 75052-0001-01 | False | | 8/6/2025 | 220 | HepB recombinant, 3-antigen, Al(OH)3 | VBI |
| 76420-0482-01 | Medical Provider Single Use EZ Flu Shot 2013-2014 | MedChem Manufacturing Inc. dba Enovachem | 5/30/2013 | 6/30/2014 | | 7/13/2018 | 76420-0482-01 | True | | 5/30/2018 | 150 | Influenza, split virus, quadrivalent, PF | PMC |
| 76420-0483-01 | Medical Provider Single Use EZ Flu Shot 2013-2014 | MedChem Manufacturing Inc. dba Enovachem | 5/30/2013 | 6/30/2014 | | 7/13/2018 | 76420-0483-01 | True | | 5/30/2018 | 150 | Influenza, split virus, quadrivalent, PF | PMC |
| 80631-0100-10 | NOVAVAX COVID-19 Vaccine, Adjuvanted | Novavax, Inc. | 3/1/2022 | 10/3/2023 | | 7/29/2024 | 80631-0100-01 | False | | 7/29/2024 | 211 | COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL | NVX |
| 80631-0102-10 | NOVAVAX COVID-19 Vaccine, Adjuvanted | Novavax, Inc. | 2/1/2023 | 10/3/2023 | | 7/29/2024 | 80631-0102-01 | False | | 7/29/2024 | 211 | COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL | NVX |
| 80631-0105-02 | NOVAVAX COVID-19 Vaccine, Adjuvanted | Novavax, Inc. | 9/1/2023 | 7/29/2024 | | 8/6/2024 | 80631-0105-01 | False | | 8/6/2024 | 313 | COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL | NVX |
| 80631-0107-10 | NOVAVAX COVID-19 VACCINE, ADJUVANTED | Novavax, Inc. | 8/30/2024 | 8/27/2025 | | 9/9/2025 | 80631-0107-01 | False | | 9/9/2025 | 313 | COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL | NVX |
| 80631-0207-10 | NUVAXOVID COVID-19 Vaccine, Adjuvanted | Novavax, Inc. | 8/27/2025 | | 00380631207109 | 11/13/2025 | 80631-0207-01 | False | 0380631207017 | 11/13/2025 | 313 | COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL | NVX |
| 80777-0100-99 | Spikevax | Moderna US, Inc. | 6/1/2022 | 4/18/2023 | | 10/24/2023 | 80777-0100-11 | False | | 10/24/2023 | 207 | COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose | MOD |
| 80777-0102-93 | Spikevax | Moderna US, Inc. | 9/11/2023 | 8/21/2024 | 00380777102931 | 9/24/2024 | 80777-0102-01 | False | 00380777102016 | 9/24/2024 | 312 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | MOD |
| 80777-0102-95 | Spikevax | Moderna US, Inc. | 9/11/2023 | 8/21/2024 | 00380777102955 | 9/24/2024 | 80777-0102-04 | False | 00380777102047 | 9/24/2024 | 312 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | MOD |
| 80777-0102-96 | Spikevax | Moderna US, Inc. | 9/11/2023 | 8/21/2024 | 00380777102962 | 9/24/2024 | 80777-0102-01 | False | 00380777102016 | 9/24/2024 | 312 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | MOD |
| 80777-0110-93 | Spikevax | Moderna US, Inc. | 8/22/2024 | 8/27/2025 | 00380777110936 | 9/9/2025 | 80777-0110-01 | False | 00380777110011 | 9/9/2025 | 312 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | MOD |
| 80777-0110-96 | Spikevax | Moderna US, Inc. | 8/22/2024 | 8/27/2025 | 00380777110967 | 9/9/2025 | 80777-0110-01 | False | 00380777110011 | 9/9/2025 | 312 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | MOD |
| 80777-0112-88 | Spikevax | Moderna US, Inc. | 8/27/2025 | | 00380777112886 | 11/13/2025 | 80777-0112-01 | False | 00380777112015 | 11/13/2025 | 312 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | MOD |
| 80777-0112-93 | Spikevax | Moderna US, Inc. | 8/27/2025 | | | 9/8/2025 | 80777-0112-01 | False | 00380777112015 | 11/13/2025 | 312 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | MOD |
| 80777-0112-96 | Spikevax | Moderna US, Inc. | 8/27/2025 | | 00380777112961 | 11/13/2025 | 80777-0112-01 | False | 00380777112015 | 11/13/2025 | 312 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | MOD |
| 80777-0113-80 | Spikevax | Moderna US, Inc. | 8/27/2025 | | 00380777113807 | 11/13/2025 | 80777-0113-09 | False | 00380777113098 | 11/13/2025 | 311 | COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL | MOD |
| 80777-0113-87 | Spikevax | Moderna US, Inc. | 8/27/2025 | | 00380777113876 | 11/13/2025 | 80777-0113-09 | False | 00380777113098 | 11/13/2025 | 311 | COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL | MOD |
| 80777-0273-98 | Moderna COVID-19 Vaccine | Moderna US, Inc. | 4/1/2021 | 4/18/2023 | | 5/30/2023 | 80777-0273-15 | False | | 5/30/2023 | 207 | COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose | MOD |
| 80777-0273-99 | Moderna COVID-19 Vaccine | Moderna US, Inc. | 12/18/2020 | 4/18/2023 | | 5/30/2023 | 80777-0273-10 | False | | 5/30/2023 | 207 | COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose | MOD |
| 80777-0275-99 | Moderna COVID-19 Vaccine | Moderna US, Inc. | 3/29/2022 | 4/18/2023 | | 5/30/2023 | 80777-0275-05 | False | | 5/30/2023 | 221 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose | MOD |
| 80777-0277-99 | Moderna COVID-19 Vaccine | Moderna US, Inc. | 6/1/2022 | 6/1/2022 | | 5/30/2023 | 80777-0277-05 | False | | 5/30/2023 | 227 | COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose | MOD |
| 80777-0279-99 | Moderna COVID-19 Vaccine | Moderna US, Inc. | 6/1/2022 | 4/18/2023 | | 5/30/2023 | 80777-0279-05 | False | | 5/30/2023 | 228 | COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose | MOD |
| 80777-0282-99 | Moderna COVID-19 Vaccine, Bivalent | Moderna US, Inc. | 7/28/2022 | 9/11/2023 | | 10/26/2023 | 80777-0282-05 | False | | 10/26/2023 | 229 | COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose | MOD |
| 80777-0283-99 | Moderna COVID-19 Vaccine, Bivalent | Moderna US, Inc. | 9/23/2022 | 9/11/2023 | | 10/26/2023 | 80777-0283-02 | False | | 10/26/2023 | 230 | COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL | MOD |
| 80777-0287-92 | Moderna COVID-19 Vaccine | Moderna US, Inc. | 9/11/2023 | 8/21/2024 | | 8/30/2024 | 80777-0287-07 | False | | 8/30/2024 | 311 | COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL | MOD |
| 80777-0291-80 | Moderna COVID-19 Vaccine | Moderna US, Inc. | 8/22/2024 | 8/27/2025 | 00380777291802 | 9/9/2025 | 80777-0291-09 | False | 00380777291093 | 9/9/2025 | 311 | COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL | MOD |
| 80777-0291-81 | Moderna COVID-19 Vaccine | Moderna US, Inc. | 8/22/2024 | 8/27/2025 | | 9/9/2025 | 80777-0291-09 | False | 00380777291093 | 9/9/2025 | 311 | COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL | MOD |
| 80777-0345-61 | mRESVIA | Moderna US, INC. | 7/1/2025 | | | 7/16/2025 | 80777-0345-01 | False | 00380777345017 | 1/21/2025 | 326 | RSV, mRNA, injectable, PF | MOD |
| 80777-0345-62 | mRESVIA | Moderna US, INC. | 7/1/2025 | | | 7/16/2025 | 80777-0345-01 | False | 00380777345017 | 1/21/2025 | 326 | RSV, mRNA, injectable, PF | MOD |
| 80777-0345-63 | mRESVIA | Moderna US, INC. | 7/1/2025 | | | 7/16/2025 | 80777-0345-01 | False | 00380777345017 | 1/21/2025 | 326 | RSV, mRNA, injectable, PF | MOD |
| 80777-0345-89 | mRESVIA | Moderna US, INC. | 11/5/2024 | | 00380777345895 | 1/21/2025 | 80777-0345-01 | False | 00380777345017 | 1/21/2025 | 326 | RSV, mRNA, injectable, PF | MOD |
| 80777-0345-90 | mRESVIA | Moderna US, INC. | 5/31/2024 | | | 6/11/2024 | 80777-0345-01 | False | 00380777345017 | 1/21/2025 | 326 | RSV, mRNA, injectable, PF | MOD |
| 80777-0345-96 | mRESVIA | Moderna US, INC. | 5/31/2024 | | 00380777345963 | 1/21/2025 | 80777-0345-01 | False | 00380777345017 | 1/21/2025 | 326 | RSV, mRNA, injectable, PF | MOD |
| 80777-0400-60 | mNEXSPIKE | Moderna US, Inc. | 8/27/2025 | | 00380777400600 | 11/13/2025 | 80777-0400-17 | False | 00380777400174 | 11/13/2025 | 334 | COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL | MOD |
| 80777-0400-61 | mNEXSPIKE | Moderna US, Inc. | 8/27/2025 | | | 9/8/2025 | 80777-0400-17 | False | 00380777400174 | 11/13/2025 | 334 | COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL | MOD |
| 80777-0400-62 | mNEXSPIKE | Moderna US, Inc. | 8/27/2025 | | | 9/8/2025 | 80777-0400-17 | False | 00380777400174 | 11/13/2025 | 334 | COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL | MOD |